

# CITATION REPORT

List of articles citing

**Safety, activity, and immune correlates of anti-PD-1 antibody in cancer**

**DOI: 10.1056/nejmoa1200690**

**New England Journal of Medicine, 2012, 366, 2443-54.**

**Source:** <https://exaly.com/paper-pdf/54021671/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2257	Adaptive immunity in cancer immunology and therapeutics. <b>2014</b> , 8, 441		26
2256	Calcium-induced contraction of the rhizoplast of a quadriflagellate green alga. <b>1978</b> , 202, 975-7		161
2255	Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. <b>2017</b> , 6, 148-158		26
2254	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. <b>2017</b> , 6, 178-185		16
2253	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <b>2017</b> , 6, 169-177		2
2252	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. <b>2017</b> , 6, 220-229		9
2251	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. <b>2017</b> , 6, 119-130		10
2250	Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. <b>2008</b> , 181, 7660-9		147
2249	Drug targets and predictive biomarkers in the management of metastatic melanoma. <b>2012</b> , 5, 139-48		3
2248	The cancer antigenome. <b>2013</b> , 32, 194-203		172
2247	Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. <b>2012</b> , 4, 2650-69		79
2246	Actualities in Medicine. <b>2012</b> , 8, 511-515		
2245	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. <b>2012</b> , 2012, 485156		64
2244	Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. <b>2012</b> , 12, 1545-57		12
2243	Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. <b>2012</b> , 209, 2485-99		127
2242	Immunotherapies: the blockade of inhibitory signals. <b>2012</b> , 8, 1420-30		23
2241	New therapies in the treatment of melanoma. <b>2012</b> , 21, 1643-59		8

2240	How can chemoimmunotherapy best be used for the treatment of colon cancer?. <b>2012</b> , 4, 1787-90	2
2239	AACR Cancer Progress Report 2012. <b>2012</b> , 18, S1-100	20
2238	The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. <b>2012</b> , 4, 1081-5	6
2237	Targeted therapy for squamous cell lung cancer. <b>2012</b> , 1, 293-300	30
2236	Antigen shedding into the circulation contributes to tumor immune escape. <b>2012</b> , 1, 1620-1622	5
2235	Progress in immunotherapy of cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1168; author reply 1168	59.2 4
2234	Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. <b>2012</b> , 1, 1617-1619	11
2233	Stereotactic body radiotherapy treatment of extracranial metastases. <b>2012</b> , 9, 654-65	35
2232	Notable advances 2012. <b>2012</b> , 18, 1732-1734	78
2231	Don't run before you can walk. <b>2012</b> , 9, 602	
2230	Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. <b>2012</b> , 19, 811-7	15
2229	Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. <b>2012</b> , 189, 4674-83	172
2228	Changing the tumor microenvironment: new strategies for immunotherapy. <b>2012</b> , 72, 5159-64	22
2227	Immunotherapeutic applications of IL-15. <b>2012</b> , 4, 957-69	27
2226	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. <b>2012</b> , 1, 1223-1225	248
2225	ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. <b>2012</b> , 72, 6130-41	134
2224	Clinical opportunities in combining immunotherapy with radiation therapy. <b>2012</b> , 2, 169	29
2223	The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. <b>2012</b> , 2012, 761518	10

2222	Immunotherapy for prostate cancer enters its golden age. <b>2012</b> , 6, 263-73	6
2221	Cell-intrinsic abrogation of TGF- $\beta$ signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. <b>2012</b> , 189, 3936-46	19
2220	Immunotherapy in breast cancer - towards a new understanding of both tumor and host. <b>2012</b> , 7, 258-60	1
2219	Immunotherapeutic approaches to hepatocellular carcinoma treatment. <b>2012</b> , 1, 226-37	43
2218	Immune therapies for lung cancer. <b>2012</b> , 7, S394-6	
2217	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. <b>2012</b> , 98, 751-755	134
2216	A major player "gets in the act". <b>2012</b> , 35, 595-7	
2215	Vaccines for pancreatic cancer. <b>2012</b> , 18, 642-52	31
2214	A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma. <b>2012</b> , 2, 883-893	1
2213	Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. <b>2012</b> , 120, 2229-39	58
2212	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. <b>2012</b> , 18, 6580-7	415
2211	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. <b>2012</b> , 25, 819-31	40
2210	Immunology beats cancer: a blueprint for successful translation. <b>2012</b> , 13, 1129-32	130
2209	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. <b>2012</b> , 12, 1437-48	21
2208	Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. <b>2012</b> , 37, 1130-44	337
2207	Gone baby gone - but how?. <b>2012</b> , 120, 4664-6	
2206	A rapidly progressing lymphocyte exhaustion after severe sepsis. <b>2012</b> , 16, 140	14
2205	Bioinformatics for cancer immunology and immunotherapy. <b>2012</b> , 61, 1885-903	32

2204	[PD-1 Antibodies. A new therapeutic option for metastatic malignant melanoma]. <b>2012</b> , 63, 724-5	0
2203	Therapeutic application of monoclonal antibodies in cancer: advances and challenges. <b>2012</b> , 104, 41-59	52
2202	Melanoma brain metastasis: overview of current management and emerging targeted therapies. <b>2012</b> , 12, 1207-15	57
2201	Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. <b>2012</b> , 18, 1248-53	291
2200	PD-1 blockade: promoting endogenous anti-tumor immunity. <b>2012</b> , 12, 1279-82	11
2199	Thinking inside the box: how T cell inhibitory receptors signal. <b>2012</b> , 18, 1338-9	8
2198	Targeted therapy in rare cancers--adopting the orphans. <b>2012</b> , 9, 631-42	25
2197	When progressive disease does not mean treatment failure: reconsidering the criteria for progression. <b>2012</b> , 104, 1534-41	96
2196	Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. <b>2012</b> , 18, 5761-72	45
2195	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. <b>2012</b> , 490, 412-6	397
2194	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. <b>2012</b> , 48, 2375-90	199
2193	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. <b>2012</b> , 10, 169	114
2192	Anti-tumor immunity: myeloid leukocytes control the immune landscape. <b>2012</b> , 278, 21-6	18
2191	Immunotherapy for castration-resistant prostate cancer. <b>2012</b> , 39, 465-81	6
2190	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. <b>2012</b> , 30, 648-57	85
2189	Cholesterol and the development of clear-cell renal carcinoma. <b>2012</b> , 12, 742-50	37
2188	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. <b>2012</b> , 12, 1597-611	94
2187	[What's new in oncology?]. <b>2012</b> , 139 Suppl 5, S217-22	

2186	Cancer: PD1 makes waves in anticancer immunotherapy. <b>2012</b> , 11, 601		21
2185	PD-1 blockade enhances T-cell migration to tumors by elevating IFN- $\gamma$ -inducible chemokines. <b>2012</b> , 72, 5209-18		288
2184	Improving lung cancer survival; time to move on. <b>2012</b> , 12, 77		23
2183	Dabrafenib and its potential for the treatment of metastatic melanoma. <b>2012</b> , 6, 391-405		70
2182	A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. <b>2012</b> , 10, 218		1
2181	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 2455-65	59.2	5527
2180	Towards an HIV cure: a global scientific strategy. <b>2012</b> , 12, 607-14		414
2179	When transgenes shape immunity: cancer immune-gene therapy. <b>2012</b> , 14, 384-5		1
2178	From ASCO-immunotherapy: programming cancer cell death. <b>2012</b> , 9, 427		
2177	Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. <b>2012</b> , 61, 2377-8		1
2176	Cautious optimism surrounds early clinical data for PD-1 blocker. <b>2012</b> , 30, 729-30		7
2175	Tumor immunotherapy directed at PD-1. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 2517-9	59.2	476
2174	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. <b>2013</b> , 11, 147		44
2173	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. <b>2013</b> , 11, 54		91
2172	Targeting the immune system for management of NSCLC: the revival?. <b>2013</b> , 2, 22-39		1
2171	Amgen announces oncolytic virus shrinks tumors. <b>2013</b> , 31, 471-2		12
2170	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. <b>2013</b> , 5, 859-68		8
2169	The immune microenvironment of human tumors: general significance and clinical impact. <b>2013</b> , 6, 117-22		93

2168	Potential biofluid markers and treatment targets for renal cell carcinoma. <b>2013</b> , 10, 336-44		20
2167	Cracking the code of human T-cell immunity. <b>2013</b> , 31, 609-10		7
2166	Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 173-83	59.2	27
2165	Nivolumab plus ipilimumab in advanced melanoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 122-33	59.2	3118
2164	Cell mates: paracrine and stromal targets for prostate cancer therapy. <b>2013</b> , 10, 441-51		28
2163	Resistance to Immunotherapeutic Antibodies in Cancer. <b>2013</b> ,		1
2162	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. <b>2013</b> , 6, 375-86		17
2161	Fool's gold, lost treasures, and the randomized clinical trial. <b>2013</b> , 13, 193		36
2160	Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. <b>2013</b> , 11, 4		35
2159	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. <b>2013</b> , 9, 977-90		19
2158	Impact of genetic targets on cancer therapy. Forward. <b>2013</b> , 779, v-vi		1
2157	Combination checkpoint blockade--taking melanoma immunotherapy to the next level. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 187-9	59.2	61
2156	Gene-engineered T cells for cancer therapy. <b>2013</b> , 13, 525-41		340
2155	Update in lung cancer and mesothelioma 2012. <b>2013</b> , 188, 157-66		23
2154	New targets in non-small cell lung cancer. <b>2013</b> , 15, 411-23		12
2153	Novel immunotherapies in GU malignancies. <b>2013</b> , 15, 224-31		4
2152	Cabozantinib as a novel therapy for renal cell carcinoma. <b>2013</b> , 15, 76-82		45
2151	Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. <b>2013</b> , 15, 98-104		35

2150	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. <b>2013</b> , 1, 11	49
2149	Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012. <b>2013</b> , 1, 9	2
2148	Les mélanomes métastatiques : vers un traitement personnalisé <b>2013</b> , 1	
2147	Metastatic melanoma to the brain: surgery and radiation is still the standard of care. <b>2013</b> , 14, 264-79	15
2146	Effector CD4 and CD8 T cells and their role in the tumor microenvironment. <b>2013</b> , 6, 123-33	190
2145	Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. <b>2013</b> , 17, R85	171
2144	Oncology meets immunology: the cancer-immunity cycle. <b>2013</b> , 39, 1-10	3130
2143	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. <b>2013</b> , 26, 1307-19	84
2142	Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. <b>2013</b> , 49, 2968-71	70
2141	Management of non-small-cell lung cancer: recent developments. <b>2013</b> , 382, 709-19	563
2140	Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. <b>2013</b> , 62, 1381-92	54
2139	Immune-suppressive properties of the tumor microenvironment. <b>2013</b> , 62, 1137-48	148
2138	Fc $\gamma$ RB controls the potency of agonistic anti-TNFR mAbs. <b>2013</b> , 62, 941-8	33
2137	Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. <b>2013</b> , 62, 629-37	40
2136	Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. <b>2013</b> , 62, 811-22	85
2135	Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. <b>2013</b> , 71, 183-91	36
2134	Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. <b>2013</b> , 73, 517-32	5
2133	Targeting the immune system in the treatment of non-small-cell lung cancer. <b>2013</b> , 14, 580-94	11



2132	Deciphering and reversing tumor immune suppression. <b>2013</b> , 39, 61-73	392
2131	B7 family checkpoint regulators in immune regulation and disease. <b>2013</b> , 34, 556-63	212
2130	New therapeutic options in systemic treatment of advanced cutaneous melanoma. <b>2013</b> , 22, 181-90	11
2129	Does a reasonable treatment approach beyond second-line exist?. <b>2013</b> , 11, 169-71	
2128	Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. <b>2013</b> , 15, 913-24	26
2127	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. <b>2013</b> , 25, 182-90	39
2126	[Medical treatment of renal cell carcinoma]. <b>2013</b> , 23, 1225-37	2
2125	The quest to overcome resistance to EGFR-targeted therapies in cancer. <b>2013</b> , 19, 1389-400	684
2124	Radiation therapy and immunotherapy: implications for a combined cancer treatment. <b>2013</b> , 85, 278-87	50
2123	Individualising treatment choices in a crowded treatment algorithm. <b>2013</b> , 11, 160-8	2
2122	Metastatic melanoma: New paradigms of treatment and new toxicities. <b>2013</b> , 11, 278-80	1
2121	Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. <b>2013</b> , 19, 4917-24	202
2120	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. <b>2013</b> , 73, 3591-603	475
2119	Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. <b>2013</b> , 41, 68-76	13
2118	Immune modulation by genetic modification of dendritic cells with lentiviral vectors. <b>2013</b> , 176, 1-15	17
2117	Management of primary cutaneous and metastatic melanoma. <b>2013</b> , 29, 195-205	12
2116	Turning tumors into vaccines: co-opting the innate immune system. <b>2013</b> , 39, 27-37	72
2115	A "big data" view of the tumor "immunome". <b>2013</b> , 39, 631-2	15

2114	Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. <b>2013</b> , 20, 946-55	106
2113	Engineering synthetic vaccines using cues from natural immunity. <b>2013</b> , 12, 978-90	403
2112	Immunotherapy for advanced melanoma: fulfilling the promise. <b>2013</b> , 39, 879-85	40
2111	Renal Cell Carcinoma. <b>2013</b> ,	3
2110	Promising systemic immunotherapies in head and neck squamous cell carcinoma. <b>2013</b> , 49, 1089-96	85
2109	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. <b>2013</b> , 31, 4199-206	384
2108	Cancer genome landscapes. <b>2013</b> , 339, 1546-58	5058
2107	Diagnosis and treatment of KIT-mutant metastatic melanoma. <b>2013</b> , 31, 3176-81	25
2106	Immunology. Making macrophages eat cancer. <b>2013</b> , 341, 41-2	27
2105	Immunity, inflammation and cancer: a leading role for adenosine. <b>2013</b> , 13, 842-57	468
2104	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. <b>2013</b> , 14, 1212-8	611
2103	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. <b>2013</b> , 19, 3462-73	601
2102	Human dendritic cells - stars in the skin. <b>2013</b> , 43, 3147-55	27
2101	Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment. <b>2013</b> , 3, 1330-2	19
2100	Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. <b>2013</b> , 190, 4899-909	144
2099	Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. <b>2013</b> , 172, 500-6	157
2098	Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. <b>2013</b> , 13, 862-74	1306
2097	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. <b>2013</b> , 31, 860-7	1023

2096	Harnessing the immune system for the treatment of non-small-cell lung cancer. <b>2013</b> , 31, 1021-8	116
2095	Immune-checkpoint blockade and active immunotherapy for glioma. <b>2013</b> , 5, 1379-412	31
2094	Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. <b>2013</b> , 31, 4268-70	11
2093	Autoimmune effector memory T cells: the bad and the good. <b>2013</b> , 57, 12-22	62
2092	Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. <b>2013</b> , 1, 373-7	86
2091	Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. <b>2013</b> , 190, 5620-8	81
2090	Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. <b>2013</b> , 5, 200ra116	1133
2089	Handbook of Cutaneous Melanoma. <b>2013</b> ,	
2088	Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. <b>2013</b> , 191, 4121-9	70
2087	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. <b>2013</b> , 13, 1399-408	9
2086	Antibody therapeutics in cancer. <b>2013</b> , 341, 1192-8	412
2085	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. <b>2013</b> , 19, 5300-9	485
2084	Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. <b>2013</b> , 62, 1711-22	90
2083	Rational combinations of immunotherapeutics that target discrete pathways. <b>2013</b> , 1, 16	55
2082	Immune evasion in acute myeloid leukemia: current concepts and future directions. <b>2013</b> , 1,	54
2081	Primer on tumor immunology and cancer immunotherapy. <b>2013</b> , 1, 12	49
2080	Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. <b>2013</b> , 2, 357	4
2079	Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. <b>2013</b> , 20, 3106-11	39

2078	Immunotherapy for the management of advanced melanoma: the next steps. <b>2013</b> , 14, 261-72	14
2077	Cancer immunotherapy: are we there yet?. <b>2013</b> , 2, 33	20
2076	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. <b>2013</b> , 13, 561	17
2075	Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung. <b>2013</b> , 14, 568-79	5
2074	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). <b>2013</b> , 30, 743	14
2073	Immune therapy for kidney cancer: a second dawn?. <b>2013</b> , 40, 492-8	16
2072	Innate and adaptive immune cells in the tumor microenvironment. <b>2013</b> , 14, 1014-22	2160
2071	Advances in the development of cancer immunotherapies. <b>2013</b> , 34, 90-8	34
2070	Immunotherapy and the concept of a clinical cure. <b>2013</b> , 49, 2965-7	38
2069	Checkpoint modulation in melanoma: an update on ipilimumab and future directions. <b>2013</b> , 15, 500-8	17
2068	Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. <b>2013</b> , 19, 1100-1	24
2067	Cancer immunotherapy: current status and future directions. <b>2013</b> , 22, 765-83	18
2066	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <b>2013</b> , 25, 261-7	325
2065	Lung cancer: potential targets for immunotherapy. <b>2013</b> , 1, 551-63	55
2064	Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. <b>2013</b> , 19, 1537-45	19
2063	Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma. <b>2013</b> , 5, 607-19	3
2062	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. <b>2013</b> , 49, 3229-41	35
2061	Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. <b>2013</b> , 40, 308-21	20

2060	Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers. <b>2013</b> , 23, 529-42	12
2059	A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. <b>2013</b> , 11, 100-6	20
2058	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <b>2013</b> , 10, 588-98	145
2057	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. <b>2013</b> , 39, 11-26	554
2056	Molecular markers to predict response to therapy. <b>2013</b> , 40, 444-58	17
2055	Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy. <b>2013</b> , 353-372	1
2054	Combination therapy in metastatic renal cell cancer. <b>2013</b> , 40, 472-81	18
2053	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <b>2013</b> , 9, 391-397	9
2052	Optimal management of metastatic melanoma: current strategies and future directions. <b>2013</b> , 14, 179-94	65
2051	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. <b>2013</b> , 62, 285-97	90
2050	PD-1 targeting in cancer immunotherapy. <b>2013</b> , 119, E1-3	17
2049	Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis. <b>2013</b> , 43, 2194-205	21
2048	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. <b>2013</b> , 26, 852-60	40
2047	An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1. <b>2013</b> , 29, 1273-85	10
2046	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. <b>2013</b> , 31, 1070-80	362
2045	Towards personalized medicine in sepsis: Quest for Shangri-La?. <b>2013</b> , 17, 303	7
2044	Thyroid dysfunction as an unintended side effect of anticancer drugs. <b>2013</b> , 23, 1345-66	76
2043	Foreword. Monoclonal antibody treatment of human disease. <b>2013</b> , 13, 1-2	

2042	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. <b>2013</b> , 1, 320-31	114
2041	The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. <b>2013</b> , 19, 6924-34	54
2040	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. <b>2013</b> , 12, 1219-34	7
2039	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. <b>2013</b> , 3, 1355-63	831
2038	Advances in catheter-ablation treatment of AF. <b>2013</b> , 10, 63-4	6
2037	Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. <b>2013</b> , 73, 1547-58	146
2036	What can be learned from a chaotic cancer model?. <b>2013</b> , 322, 7-16	70
2035	Harnessing the power of the immune system to target cancer. <b>2013</b> , 64, 71-90	103
2034	Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. <b>2013</b> , 19, S2-5	27
2033	Impact of genetic markers on treatment of non-small cell lung cancer. <b>2013</b> , 779, 145-64	6
2032	Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. <b>2013</b> , 19, 28-33	147
2031	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. <b>2013</b> , 121, 1367-76	131
2030	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. <b>2013</b> , 73, 1733-41	564
2029	T cell energy, exhaustion, senescence, and stemness in the tumor microenvironment. <b>2013</b> , 25, 214-21	413
2028	Targeting oncogenic drivers and the immune system in melanoma. <b>2013</b> , 31, 499-506	82
2027	Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. <b>2013</b> , 73, 605-16	38
2026	Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. <b>2013</b> , 19, 462-8	407
2025	PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. <b>2013</b> , 73, 128-38	456

2024	The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. <b>2013</b> , 19, 598-609	330
2023	Novel immunotherapeutic strategies in development for renal cell carcinoma. <b>2013</b> , 63, 881-9	31
2022	Immune Co-signaling to Treat Cancer. <b>2013</b> , 211-280	1
2021	Microenvironment and tumor progression of melanoma: new therapeutic prospectives. <b>2013</b> , 10, 235-52	28
2020	Chemoimmunotherapy: reengineering tumor immunity. <b>2013</b> , 62, 203-16	162
2019	Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. <b>2013</b> , 19, 205-14	128
2018	Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. <b>2013</b> , 151, 71-5	42
2017	βBlocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. <b>2013</b> , 49, 3863-71	44
2016	Immunotherapy of melanoma. <b>2013</b> , 11, 97-105	39
2015	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. <b>2013</b> , 49, 1673-82	30
2014	In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. <b>2013</b> , 172, 426-35	94
2013	Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. <b>2013</b> , 6, 282-9	90
2012	[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. <b>2013</b> , 140, 266-73	17
2011	Évaluation RECIST en cancérologie thoracique. <b>2013</b> , 5, 361-366	
2010	Melanoma-associated leukoderma - immunology in black and white?. <b>2013</b> , 26, 796-804	30
2009	Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. <b>2013</b> , 29, 464-73	25
2008	[What's new in dermatology-?]. <b>2013</b> , 140 Suppl 3, S283-92	
2007	The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?. <b>2013</b> , 49, 2504-11	7

2006	Current advances in immunotherapy for pancreatic cancer. <b>2013</b> , 37, 273-9	11
2005	Mission impossible: how HPV-associated head and neck cancers escape a primed immune response. <b>2013</b> , 49, 723-5	6
2004	Translational research in melanoma. <b>2013</b> , 22, 785-804	
2003	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. <b>2013</b> , 27, 209-16	60
2002	CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. <b>2013</b> , 30, 442	21
2001	Advances in targeting cell surface signalling molecules for immune modulation. <b>2013</b> , 12, 130-46	192
2000	Adaptive resistance: a tumor strategy to evade immune attack. <b>2013</b> , 43, 576-9	15
1999	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. <b>2013</b> , 138, 105-15	491
1998	Prostate cancer vaccines. <b>2013</b> , 12, 253-62	11
1997	Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. <b>2013</b> , 14, 240-6	43
1996	Melanoma prognostics and personalized therapeutics at a crossroad. <b>2013</b> , 133, 292-5	1
1995	Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?. <b>2013</b> , 6, 173-6	6
1994	T-cell memory differentiation: insights from transcriptional signatures and epigenetics. <b>2013</b> , 139, 277-84	111
1993	Kidney cancer in 2012: new frontiers in kidney cancer research. <b>2013</b> , 10, 70-2	3
1992	Agonist antibodies to TNFR molecules that costimulate T and NK cells. <b>2013</b> , 19, 1044-53	122
1991	Emerging targeted agents in metastatic breast cancer. <b>2013</b> , 10, 191-210	138
1990	Agonistic CD40 antibodies and cancer therapy. <b>2013</b> , 19, 1035-43	300
1989	Molecular mechanisms of T cell co-stimulation and co-inhibition. <b>2013</b> , 13, 227-42	1711



1988	The search for an HIV cure: tackling latent infection. <b>2013</b> , 13, 614-21	51
1987	Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. <b>2013</b> , 81, 183-93	61
1986	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. <b>2013</b> , 13, 365-76	191
1985	The future of epigenetic therapy in solid tumours--lessons from the past. <b>2013</b> , 10, 256-66	262
1984	Novel therapies for the treatment of advanced prostate cancer. <b>2013</b> , 14, 109-26	15
1983	Endocrine side effects induced by immune checkpoint inhibitors. <b>2013</b> , 98, 1361-75	299
1982	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. <b>2013</b> , 25, 268-76	275
1981	Human cancer regression antigens. <b>2013</b> , 25, 284-90	29
1980	Immunotherapy for Renal Cell Carcinoma. <b>2013</b> , 279-301	
1979	Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. <b>2013</b> , 13, 643-56	21
1978	Coinhibitory molecules in cancer biology and therapy. <b>2013</b> , 24, 147-61	24
1977	PD-1 coinhibitory signals: the link between pathogenesis and protection. <b>2013</b> , 25, 219-27	44
1976	At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. <b>2013</b> , 94, 25-39	266
1975	The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. <b>2013</b> , 34, 193-9	15
1974	Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. <b>2013</b> , 13, 260-8	899
1973	Antibody-based therapy in colorectal cancer. <b>2013</b> , 5, 533-45	21
1972	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <b>2013</b> , 15, 342-9	23
1971	NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. <b>2013</b> , 91, 435-40	48

1970	Melanoma immunotherapy: historical precedents, recent successes and future prospects. <b>2013</b> , 5, 169-82	24
1969	Developing melanoma therapeutics: overview and update. <b>2013</b> , 5, 257-71	13
1968	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 134-44	59.2 2661
1967	Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure. <b>2013</b> , 139, 405-11	11
1966	Development of antibody therapeutics for small cell lung cancer. <b>2013</b> , 22, 235-44	7
1965	IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. <b>2013</b> , 5, 178-201	6
1964	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. <b>2013</b> , 621-642	
1963	Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. <b>2013</b> , 162, 313-25	76
1962	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. <b>2013</b> , 139, 667-76	236
1961	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. <b>2013</b> , 94, 41-53	232
1960	Update on the targeted therapy of melanoma. <b>2013</b> , 14, 280-92	40
1959	Cancer immunotherapies, their safety and toxicity. <b>2013</b> , 12, 631-45	94
1958	Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). <b>2013</b> , 94, 1201-6	8
1957	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <b>2013</b> , 76, 233-47	31
1956	What can be done for patients with NSCLC without druggable targets?. <b>2013</b> , 14, 191-2	1
1955	HIV and co-infections. <b>2013</b> , 254, 114-42	81
1954	Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. <b>2013</b> , 14, 249-63	48
1953	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <b>2013</b> , 1291, 1-13	215

1952	Targeted therapy for non-small-cell lung cancer: past, present and future. <b>2013</b> , 13, 745-58	68
1951	Which drug, and when, for patients with BRAF-mutant melanoma?. <b>2013</b> , 14, e60-9	147
1950	Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. <b>2013</b> , 40, 347-60	13
1949	Therapeutic vaccines for ovarian cancer. <b>2013</b> , 130, 667-73	12
1948	Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. <b>2013</b> , 336, 253-9	61
1947	Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. <b>2013</b> , 35, 487-96	4
1946	The Tumor Immunoenvironment. <b>2013</b> ,	3
1945	B7-H5 costimulates human T cells via CD28H. <b>2013</b> , 4, 2043	111
1944	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. <b>2013</b> , 49, 2233-42	319
1943	Dendritic cell immunotherapy. <b>2013</b> , 1284, 31-45	40
1942	Cellular immunotherapy for plasma cell myeloma. <b>2013</b> , 48, 1377-86	6
1941	Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. <b>2013</b> , 12, 285-95	49
1940	The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. <b>2013</b> , 25, 230-7	124
1939	Adjuvant immunotherapies as a novel approach to bacterial infections. <b>2013</b> , 5, 365-81	11
1938	Manipulating the PD-1 pathway to improve immunity. <b>2013</b> , 25, 381-8	75
1937	Tumour heterogeneity and immune-modulation. <b>2013</b> , 13, 497-503	27
1936	Combination molecularly targeted drug therapy in metastatic melanoma: progress to date. <b>2013</b> , 73, 767-77	10
1935	Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. <b>2013</b> , 26, 544-54	33

1934 Lungenkarzinom. **2013**, 8, 20-27

1933 Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. **2013**, 20 Suppl 3, S725-30 27

1932 Better performance of CARs deprived of the PD-1 brake. **2013**, 19, 5546-8 11

1931 Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. **2013**, 19, 6151-62 80

1930 [Lung cancer. Molecular pathology and personalized therapy]. **2013**, 54, 179-80, 182-7 1

1929 [Personalized therapy concepts for malignant melanoma]. **2013**, 54, 188-93 3

1928 New landscape in the treatment of melanoma: a 2012 update. **2013**, 15, 71-77 1

1927 Characterization of distinct immunophenotypes across pediatric brain tumor types. **2013**, 191, 4880-8 126

1926 Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. **2013**, 191, 5097-106 18

1925 Clinical trials in cellular immunotherapy for brain/CNS tumors. **2013**, 13, 405-24 15

1924 Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. **2013**, 191, 1011-5 55

1923 Preclinical vaccines against mammary carcinoma. **2013**, 12, 1449-63 9

1922 T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. **2013**, 26, 441-56 11

1921 Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. **2013**, 29, 551-7 31

1920 Oncolytic vaccines. **2013**, 12, 1155-72 35

1919 Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. **2013**, 19, 997-1008 144

1918 Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. **2013**, 1, 85-91 132

1917 Ipilimumab in prostate cancer. **2013**, 13, 303-13 5

1916	OX40 is a potent immune-stimulating target in late-stage cancer patients. <b>2013</b> , 73, 7189-7198	341
1915	Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. <b>2013</b> , 22, 1385-400	8
1914	The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. <b>2013</b> , 19, 5283-91	45
1913	Emerging BRAF inhibitors for melanoma. <b>2013</b> , 18, 431-43	5
1912	Recent advances in the treatment of metastatic renal cell carcinoma. <b>2013</b> , 20, 944-55	44
1911	Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. <b>2013</b> , 31, 4311-8	447
1910	Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. <b>2013</b> , 21, 2122-9	299
1909	Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. <b>2013</b> , 191, 2829-36	50
1908	Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. <b>2013</b> , 62, 529-39	19
1907	MAP kinase signaling and inhibition in melanoma. <b>2013</b> , 32, 2373-9	111
1906	Personalized Management of Lung Cancer. <b>2013</b> ,	
1905	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <b>2013</b> , 8, 479-487	3
1904	Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN- $\gamma$ production. <b>2013</b> , 19, 668-79	17
1903	Koch Institute Symposium on Cancer Immunology and Immunotherapy. <b>2013</b> , 1, 217-222	0
1902	Immunotherapeutic strategies including transplantation: eradication of disease. <b>2013</b> , 2013, 151-7	10
1901	Advances in personalized therapy for lung cancer. <b>2013</b> , 7, 475-85	8
1900	Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. <b>2013</b> , 2, e22691	28
1899	AACR Cancer Progress Report 2013. <b>2013</b> , 19, S4-98	47

1898	A new role for NFB in immunosurveillance and its implications for cancer immunotherapy. <b>2013</b> , 2, e25963	3
1897	Getting personal with neoantigen-based therapeutic cancer vaccines. <b>2013</b> , 1, 11-5	133
1896	Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients. <b>2013</b> , 5, 557-9	2
1895	Immune aspects of the breast tumor microenvironment. <b>2013</b> , 2, 231-244	11
1894	[Perspectives on immunotherapy for hepatocellular carcinoma]. <b>2013</b> , 138, 740-4	2
1893	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. <b>2013</b> , 22, 565-76	18
1892	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. <b>2013</b> , 7, 23-35	7
1891	[Malignant pleural mesothelioma: 2013 state of the art]. <b>2013</b> , 100, 1283-93	5
1890	CD4 T-cell immunotherapy for chronic viral infections and cancer. <b>2013</b> , 5, 975-87	43
1889	Immunotherapy treatments for small-cell lung cancer: past, present and future. <b>2013</b> , 2, 517-525	1
1888	[Immune-checkpoints: the new anti-cancer immunotherapies]. <b>2013</b> , 100, 601-10	7
1887	New therapeutic targets and drugs for the treatment of chronic hepatitis B. <b>2013</b> , 33, 130-7	21
1886	Virosome presents multimodel cancer therapy without viral replication. <b>2013</b> , 2013, 764706	18
1885	Diet, obesity, and cancer progression: are adipocytes the link?. <b>2013</b> , 6, 37-45	14
1884	Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. <b>2013</b> , 4, 435	16
1883	Combination immune therapies to enhance anti-tumor responses by NK cells. <b>2013</b> , 4, 481	57
1882	Antibody therapy of pediatric B-cell lymphoma. <b>2013</b> , 3, 68	3
1881	Immunotherapy and immune evasion in prostate cancer. <b>2013</b> , 5, 569-90	17

1880	Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN- $\gamma$ -mediated CD8(+) T cell cytotoxicity. <b>2013</b> , 35, 623-31	34
1879	Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. <b>2013</b> , 9, e1003215	44
1878	Improvement of cancer immunotherapy by combining molecular targeted therapy. <b>2013</b> , 3, 136	19
1877	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. <b>2013</b> , 12, 7	10
1876	Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. <b>2013</b> , 2013, 371854	52
1875	Improving drug uptake and penetration into tumors: current and forthcoming opportunities. <b>2013</b> , 3, 161	5
1874	Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. <b>2013</b> , 4, 346	31
1873	The role of the immune response in merkel cell carcinoma. <b>2013</b> , 5, 234-54	28
1872	TIM-3 does not act as a receptor for galectin-9. <b>2013</b> , 9, e1003253	68
1871	Xiao-Ai-Ping, a TCM Injection, Enhances the Antigrowth Effects of Cisplatin on Lewis Lung Cancer Cells through Promoting the Infiltration and Function of CD8(+) T Lymphocytes. <b>2013</b> , 2013, 879512	15
1870	T-cell costimulatory blockade in organ transplantation. <b>2013</b> , 3, a015537	13
1869	Dendritic cell based vaccines for HIV infection: the way ahead. <b>2013</b> , 9, 2445-52	49
1868	Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. <b>2013</b> , 2, e26014	16
1867	Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. <b>2013</b> , 36, 382-9	393
1866	A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy. <b>2013</b> , 36, 400-11	7
1865	Renal cell carcinoma: trying but failing to improve the only curative therapy. <b>2013</b> , 36, 459-61	2
1864	Vaccine and immunotherapeutic interventions. <b>2013</b> , 8, 236-42	17
1863	Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. <b>2013</b> , 19, 25-33	10

1862	Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. <b>2013</b> , 19, 50-8	17
1861	Emerging immunotherapies in older adults with acute myeloid leukemia. <b>2013</b> , 20, 107-14	6
1860	Immune activation and HIV persistence: considerations for novel therapeutic interventions. <b>2013</b> , 8, 211-6	57
1859	Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. <b>2013</b> , 19, 247-62	14
1858	Immunotherapy of sarcomas. <b>2013</b> , 25, 390-7	4
1857	Current world literature. State of HIV cure. <b>2013</b> , 8, 250-3	
1856	Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. <b>2013</b> , 36, 248-57	38
1855	CD40 therapy and surgery: a potential immunologic partnership. <b>2013</b> , 36, 359-61	5
1854	Curing HIV: lessons from cancer therapy. <b>2013</b> , 8, 224-9	10
1853	Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. <b>2013</b> , 2, e26091	6
1852	Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. <b>2013</b> , 2, e23972	30
1851	PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. <b>2013</b> , 5, 215ra172	435
1850	Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion. <b>2013</b> , 3, 20130010	41
1849	New developments in biomarkers for melanoma. <b>2013</b> , 25, 145-51	17
1848	Cancer vaccines: Looking to the future. <b>2013</b> , 2, e23403	45
1847	Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. <b>2013</b> , 36, 442-50	20
1846	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. <b>2013</b> , 2, e26615	82
1845	Second-Line Therapy for Advanced NSCLC. <b>2013</b> , 18, 947-53	30



1844	Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. <b>2013</b> , 73, 4820-9	79
1843	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. <b>2013</b> , 19, 1021-34	381
1842	PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. <b>2013</b> , 19, 1363-74	151
1841	Recent developments in the treatment of renal cell carcinoma. <b>2013</b> , 5, 338-53	57
1840	Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. <b>2013</b> , 24, 1170-9	64
1839	HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. <b>2013</b> , 73, 1764-76	62
1838	What lies within: novel strategies in immunotherapy for non-small cell lung cancer. <b>2013</b> , 18, 1203-13	30
1837	Drug development: Releasing the brakes. <b>2013</b> , 504, S6-8	15
1836	Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. <b>2013</b> , 210, 2435-66	197
1835	Tumor-specific T-cell help is associated with improved survival in melanoma. <b>2013</b> , 19, 4021-3	13
1834	Molecular insights for optimizing T cell receptor specificity against cancer. <b>2013</b> , 4, 154	27
1833	New treatment approaches in melanoma: current research and clinical prospects. <b>2013</b> , 5, 73-80	16
1832	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. <b>2013</b> , 5, 249-70	34
1831	Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. <b>2013</b> , 190, 5874-81	122
1830	Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <b>2013</b> , 169, R153-64	82
1829	Design considerations for dose-expansion cohorts in phase I trials. <b>2013</b> , 31, 4014-21	38
1828	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. <b>2013</b> , 5, 105-18	31
1827	"License to kill" reflects joint action of CD4 and CD8 T cells. <b>2013</b> , 19, 4295-6	21

1826	Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. <b>2013</b> , 1, 99-111	37
1825	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. <b>2013</b> , 123, 2604-15	174
1824	Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. <b>2013</b> , 24, 543-9	29
1823	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. <b>2013</b> , 5, 278-85	21
1822	Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. <b>2013</b> , 19, 5351-60	143
1821	Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. <b>2013</b> , 19, 3936-43	331
1820	Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. <b>2013</b> , 1, 123-33	52
1819	Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011. <b>2013</b> , 23, 152-8	2
1818	Is interleukin 2 the best initial therapy for many patients with metastatic renal cell carcinoma?. <b>2013</b> , 19, 197-8	1
1817	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. <b>2013</b> , 210, 757-74	169
1816	Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. <b>2013</b> , 4, 221	31
1815	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. <b>2013</b> , 4, 363	64
1814	Evolving pharmacotherapies for the treatment of metastatic melanoma. <b>2013</b> , 7, 137-49	6
1813	Immunotherapy in advanced cutaneous melanoma patients. <b>2013</b> , 5, 429-433	
1812	Influence of tumors on protective anti-tumor immunity and the effects of irradiation. <b>2013</b> , 3, 14	7
1811	Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. <b>2013</b> , 4, 244	61
1810	Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function. <b>2013</b> , 78, 239-247	29
1809	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. <b>2014</b> , 3, 1-8	4

1808	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. <b>2013</b> , 2013, 168145	114
1807	Control of in vivo collateral damage generated by T cell immunity. <b>2013</b> , 191, 1686-91	14
1806	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <b>2013</b> , 2, e25564	6
1805	Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. <b>2013</b> , 2, e26286	86
1804	Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. <b>2013</b> , 19, 4843-53	48
1803	Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. <b>2014</b> , 95, 24-31	68
1802	Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?. <b>2013</b> , 26, 167-75	9
1801	New horizons for prostate cancer: part 1. <b>2013</b> , 4, 38-40	
1800	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. <b>2013</b> , 1, 54-63	277
1799	Ongoing adaptive immune responses in the microenvironment of melanoma metastases. <b>2013</b> , 1284, 62-5	3
1798	Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. <b>2013</b> , 31, e439-42	631
1797	Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. <b>2013</b> , 65, 1351-95	26
1796	Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. <b>2013</b> , 93, 1247-88	258
1795	Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). <b>2013</b> , 110, 15001-6	134
1794	Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. <b>2013</b> , 231, 424-32	83
1793	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. <b>2013</b> , 5, 169-81	121
1792	PD-1 as a potential target in cancer therapy. <b>2013</b> , 2, 662-73	306
1791	Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. <b>2013</b> , 18, 532-41	13

1790	Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. <b>2013</b> , 73, 2381-8	115
1789	The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans. <b>2013</b> , 191, 3673-80	64
1788	Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. <b>2013</b> , 191, 540-4	117
1787	Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. <b>2013</b> , 191, 4174-83	74
1786	CTLA4Ig inhibits effector T cells through regulatory T cells and TGF- $\beta$ <b>2013</b> , 191, 3082-9	33
1785	Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. <b>2013</b> , 2, e27010	36
1784	High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored?. <b>2013</b> , 2, e24679	10
1783	High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies. <b>2013</b> , 2, e26704	2
1782	Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. <b>2013</b> , 31, 131-61	35
1781	RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response. <b>2013</b> , 19, 5686-98	19
1780	Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. <b>2013</b> , 2, e24065	12
1779	Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. <b>2013</b> , 1, 378-85	31
1778	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. <b>2013</b> , 6, 381-95	28
1777	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. <b>2013</b> , 98, 953-63	148
1776	Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. <b>2013</b> , 2, e24320	36
1775	Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. <b>2013</b> , 2, e23661	21
1774	Trial watch: Monoclonal antibodies in cancer therapy. <b>2013</b> , 2, e22789	76
1773	[Targeted therapy: old and new possibilities]. <b>2013</b> , 36 Suppl 5, 2-11	1

1772	Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. <b>2013</b> , 27, 2251-3	36
1771	The delicate balance of melanoma immunotherapy. <b>2013</b> , 2, e5	21
1770	Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. <b>2013</b> , 16, 123-31, S1	29
1769	Genomic medicine frontier in human solid tumors: prospects and challenges. <b>2013</b> , 31, 1874-84	90
1768	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. <b>2013</b> , 108, 1560-5	114
1767	Optimal conditions required for influenza A infection-enhanced cross-priming of CD8+ T cells specific to cell-associated antigens. <b>2013</b> , 91, 576-82	2
1766	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. <b>2013</b> , 19, 5636-46	485
1765	Immune alterations in malignant melanoma and current immunotherapy concepts. <b>2013</b> , 13, 1413-27	19
1764	Adoptive T-cell transfer in melanoma. <b>2013</b> , 5, 79-90	19
1763	Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. <b>2013</b> , 73, 2435-44	185
1762	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. <b>2013</b> , 19, 5626-35	293
1761	Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. <b>2013</b> , 2, e25994	13
1760	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. <b>2013</b> , 110, 9879-84	113
1759	Vaccine therapy for pancreatic cancer. <b>2013</b> , 2, e26662	40
1758	Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. <b>2013</b> , 19, 1009-20	113
1757	A focus on PD-L1 in human melanoma. <b>2013</b> , 19, 514-6	15
1756	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. <b>2013</b> , 2, e23991	42
1755	Molecular profiling of tumor-specific T1 cells activated in vivo. <b>2013</b> , 2, e24383	11

1754	Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. <b>2013</b> , 5, 1347-55	4
1753	The immunological identity of tumor: Self implications. <b>2013</b> , 2, e23794	4
1752	SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. <b>2013</b> , 2, e25205	46
1751	Inhibiting the inhibitors: Checkpoints blockade in solid tumors. <b>2013</b> , 2, e26535	15
1750	Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. <b>2013</b> , 19, 2224-31	42
1749	MAGE-A3-specific anticancer immunotherapy in the clinical practice. <b>2013</b> , 2, e25995	13
1748	PD-L1 expression in B-cell lymphomas and virus-associated malignancies--letter. <b>2013</b> , 19, 4017	3
1747	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. <b>2013</b> , 2, 381-390	
1746	Melanoma treatment: where are we now and what's on the horizon?. <b>2013</b> , 10, 237-240	
1745	gene expression in Japanese lung cancer patients. <b>2013</b> , 1, 93-96	10
1744	Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. <b>2013</b> , 122, 1399-410	64
1743	Inhibiting inhibitory pathways in human T cells. <b>2013</b> , 122, 857-8	2
1742	The role of B7 family molecules in hematologic malignancy. <b>2013</b> , 121, 734-44	132
1741	A shot in the arm for radiotherapy. <b>2013</b> , 121, 246-8	
1740	Exhausting T cells in CLL. <b>2013</b> , 121, 1485-6	21
1739	Advances in the treatment of late stage melanoma. <b>2013</b> , 346, f1265	5
1738	Immunotherapy for gastrointestinal malignancies. <b>2013</b> , 20, 32-42	25
1737	Melanoma mutagenesis and aberrant cell signaling. <b>2013</b> , 20, 261-81	20

1736	New targeted therapies in melanoma. <b>2013</b> , 20, 282-8	10
1735	Novel treatments for melanoma brain metastases. <b>2013</b> , 20, 298-306	12
1734	Vemurafenib-induced pulmonary injury. <b>2013</b> , 36, 685-6	5
1733	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. <b>2013</b> , 11, 88	124
1732	Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. <b>2013</b> , 11, 766-72	9
1731	Targeted therapy of kidney cancer: keeping the art around the algorithms. <b>2013</b> , 20, 222-32	6
1730	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. <b>2013</b> , 20, 289-97	80
1729	Blick Über die neue Melanomleitlinie hinaus. <b>2013</b> , 29, 178-181	
1728	Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. <b>2013</b> , 8, 587-98	51
1727	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). <b>2013</b> , 8, 803-5	105
1726	Current Advances in Therapy for Metastatic Melanoma. <b>2013</b> , 9, 8-23	
1725	Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. <b>2013</b> , 19, 5261-3	44
1724	Primary care for cancers at diagnosis and follow-up: a narrative review. <b>2013</b> , 1, 56-67	
1723	Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. <b>2013</b> , 19, 4347-58	66
1722	Evolutionary dynamics of cancer in response to targeted combination therapy. <b>2013</b> , 2, e00747	400
1721	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. <b>2013</b> , 14, 13958-78	39
1720	Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. <b>2013</b> , 15, R75	44
1719	Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. <b>2013</b> , 43, 919-26	5

1718	Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. <b>2013</b> , 53, 741-54	15
1717	Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. <b>2013</b> , 6, 869-75	22
1716	Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. <b>2013</b> , 6, 245-56	12
1715	Targeting immunosuppression for cancer therapy. <b>2013</b> , 123, 2355-7	42
1714	Update on the challenges and recent advances in cancer immunotherapy. <b>2013</b> , 2, 39-49	7
1713	What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer?. <b>2013</b> , 2013, 806025	19
1712	Tivozanib in the treatment of renal cell carcinoma. <b>2013</b> , 7, 139-48	14
1711	Engineering Anti-Tumor T Cell Immunity. <b>2013</b> , 02,	
1710	Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. <b>2013</b> , 2, 73-90	23
1709	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. <b>2013</b> , 6, 1119-27	14
1708	Immunotherapy for colorectal cancer. <b>2013</b> , 19, 8531-42	65
1707	T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. <b>2013</b> , 2, 135-41	3
1706	[PD-1 and PDL-1 expression in cancer: significance and prognostic value]. <b>2013</b> , 29, 570-2	7
1705	Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. <b>2013</b> , 8, e55818	92
1704	Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. <b>2013</b> , 8, e61895	108
1703	A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. <b>2013</b> , 8, e63818	181
1702	The role of the e3 ligase cbl-B in murine dendritic cells. <b>2013</b> , 8, e65178	10
1701	The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. <b>2013</b> , 8, e67876	25



1700	Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]. <b>2013</b> , 8, e75694	19
1699	Natural killer T cells in advanced melanoma patients treated with tremelimumab. <b>2013</b> , 8, e76829	14
1698	PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. <b>2013</b> , 8, e77780	75
1697	Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. <b>2013</b> , 8, e79874	28
1696	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Perspectives. <b>2013</b> ,	2
1695	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. <b>2013</b> , 4, 417	53
1694	Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. <b>2013</b> , 4, 436	14
1693	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. <b>2013</b> , 3, 54	25
1692	Chemokines as Cancer Vaccine Adjuvants. <b>2013</b> , 1, 444-62	25
1691	Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. <b>2013</b> , 2013, 875343	7
1690	Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. <b>2013</b> , 1, 2-8	12
1689	Cancer testis antigen and immunotherapy. <b>2013</b> , 2, 11-9	34
1688	Sizing up a slow assault on cancer. <b>2013</b> , 496, 14-5	4
1687	Current state-of-the-art therapy for advanced squamous cell lung cancer. <b>2013</b> , 354-8	8
1686	Melanoma vaccines: trials and tribulations. <b>2013</b> , 57	8
1685	Treating metastatic melanoma in 2014: what just happened and what is next?. <b>2014</b> , 16-9	1
1684	Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice. <b>2014</b> , e412-21	4
1683	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. <b>2014</b> , 1	1

1682	New modalities of cancer treatment for NSCLC: focus on immunotherapy. <b>2014</b> , 6, 63-75	55
1681	Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. <b>2014</b> , 6, 279-89	17
1680	Avoidance of Cancer Cell Destruction by the Immune System. <b>2014</b> , 434-443	
1679	Interferon- $\gamma$ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. <b>2014</b> , 8, 1527-38	23
1678	[Tumor hypoxia: a key player in the regulation of stromal and anti-tumor responses]. <b>2014</b> , 30, 422-8	3
1677	Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. <b>2014</b> , 8, 1539-53	8
1676	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. <b>2014</b> , 7, 567-73	172
1675	Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. <b>2014</b> , 9, e101764	172
1674	Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies. <b>2014</b> , 9, e95096	39
1673	Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. <b>2014</b> , 9, e87617	18
1672	HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection. <b>2014</b> , 9, e87631	18
1671	PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. <b>2014</b> , 9, e89350	135
1670	Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor. <b>2014</b> , 9, e104669	9
1669	Advances and Prospects in Cancer Immunotherapy. <b>2014</b> , 2014, 1-13	16
1668	Current and future roles of targeted therapy and immunotherapy in advanced melanoma. <b>2014</b> , 20, 346-56	44
1667	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. <b>2014</b> , 7, 357-65	49
1666	New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. <b>2014</b> , 6, 77-88	27
1665	Interleukin-17 and type 17 helper T cells in cancer management and research. <b>2014</b> , 3, 39-54	16

1664	Pathways and therapeutic targets in melanoma. <b>2014</b> , 5, 1701-52	158
1663	Attenuated <i>Listeria monocytogenes</i> : a powerful and versatile vector for the future of tumor immunotherapy. <b>2014</b> , 4, 51	88
1662	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. <b>2014</b> , 5, 165	99
1661	Dermatology: Where are We Coming from and Where are We Going to?. <b>2014</b> , 1, 40	
1660	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. <b>2014</b> , 4, 386-401	12
1659	Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification. <b>2014</b> , 2, 549-62	7
1658	Immunotherapy for non-small cell lung cancer. <b>2014</b> , 77, 111-5	18
1657	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. <b>2014</b> , 7, 1349-59	32
1656	Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. <b>2014</b> , 5,	24
1655	An updated overview of HPV-associated head and neck carcinomas. <b>2014</b> , 5, 3956-69	83
1654	Molecular pathways and therapeutic targets in lung cancer. <b>2014</b> , 5, 1392-433	135
1653	PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. <b>2014</b> , 5, 166-72	116
1652	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. <b>2014</b> , 8, 775-87	25
1651	365 days: Nature's 10. <b>2014</b> , 516, 311-9	8
1650	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. <b>2014</b> , 14, 265-76	65
1649	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <b>2014</b> , 124, 2246-59	664
1648	Managing Multi-center Flow Cytometry Data for Immune Monitoring. <b>2014</b> , 13, 111-22	9
1647	Tumor Immunology. <b>2014</b> , 60, 358-361	

1646	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. <b>2014</b> , 3, 151-65	9
1645	PharmaForum. <b>2014</b> , 2, 115-117	
1644	Advances and new perspectives in the treatment of metastatic colon cancer. <b>2014</b> , 6, 211-24	20
1643	Pazopanib-the Latest First-Line Standard of Care Targeted Kinase Inhibitor for the Treatment of Advanced Renal Cell Carcinoma. <b>2014</b> , 6, CMT.S9280	
1642	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. <b>2014</b> , 5, 4516-28	20
1641	EBV-driven LMP1 and IFN- $\gamma$ regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. <b>2014</b> , 5, 12189-202	246
1640	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. <b>2014</b> ,	3
1639	Immune system offers clues to cancer treatment. <b>2014</b> ,	
1638	. <b>2014</b> ,	
1637	New agents and new targets for renal cell carcinoma. <b>2014</b> , e222-7	21
1636	50 Years of progress in the systemic therapy of non-small cell lung cancer. <b>2014</b> , 177-89	75
1635	Management of vulvar and vaginal melanomas: current and future strategies. <b>2014</b> , e277-81	33
1634	Precision cancer medicine: the future is now, only better. <b>2014</b> , 61-9	30
1633	Recent advances in immunotherapy for non-small-cell lung cancer. <b>2014</b> , 10, 352-7	13
1632	Adding fuel to the fire: immunogenic intensification. <b>2014</b> , 10, 3306-12	3
1631	IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. <b>2014</b> , 10, 3179-89	36
1630	Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. <b>2014</b> , 3, e954467	13
1629	Interleukin-15 in the treatment of cancer. <b>2014</b> , 10, 1689-701	51

1628	The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. <b>2014</b> , 5, 45-56	181
1627	PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. <b>2014</b> , 6, 737-53	14
1626	Emerging molecular targets in the treatment of nasopharyngeal carcinoma. <b>2014</b> , 189-210	
1625	Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. <b>2014</b> , 3, e954868	8
1624	Molecular pathways: interleukin-15 signaling in health and in cancer. <b>2014</b> , 20, 2044-50	118
1623	PD-1 and PD-L1 antibodies for melanoma. <b>2014</b> , 10, 3111-6	41
1622	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. <b>2014</b> , 13, 87-116	3
1621	Biomarkers in melanoma: where are we now?. <b>2014</b> , 1, 139-150	1
1620	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. <b>2014</b> , 3, e27297	86
1619	PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. <b>2014</b> , 105, 1229-35	54
1618	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. <b>2014</b> , 14, 663-86	16
1617	Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. <b>2014</b> , 3, e963413	52
1616	Immunoregulatory activity of adenosine and its role in human cancer progression. <b>2014</b> , 10, 897-914	64
1615	Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer. <b>2014</b> , 10, 3286-96	1
1614	Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. <b>2014</b> ,	
1613	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. <b>2014</b> , 3, e958952	18
1612	Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. <b>2014</b> , 10, 3354-68	53
1611	Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. <b>2014</b> , 2, 448-58	27

1610	Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax <sup>®</sup> , as a therapeutic strategy for metastatic breast cancer. <b>2014</b> , 12, 322	24
1609	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. <b>2014</b> , 2, 40	41
1608	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <b>2014</b> , 12, 291	28
1607	Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. <b>2014</b> , 96, 449-57	85
1606	New strategies in ewing sarcoma: lost in translation?. <b>2014</b> , 20, 3050-6	25
1605	Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. <b>2014</b> , 3, e28327	9
1604	Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. <b>2014</b> , 2, 38	25
1603	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive <sup>®</sup> ) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. <b>2014</b> , 14, 748	74
1602	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. <b>2014</b> , 2, 33	38
1601	New antibody approaches to lymphoma therapy. <b>2014</b> , 7, 58	44
1600	Melanoma immunotherapy. <b>2014</b> , 15, 665-74	54
1599	Im Fokus Das Nierenzellkarzinom. <b>2014</b> , 17, 23-26	
1598	Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. <b>2014</b> , 7, 91	18
1597	Lungenkarzinom. <b>2014</b> , 17, 14-21	
1596	Tissue-resident exhausted effector memory CD8+ T cells accumulate in the retina during chronic experimental autoimmune uveoretinitis. <b>2014</b> , 192, 4541-50	29
1595	Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. <b>2014</b> , 3, e27817	157
1594	When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma. <b>2014</b> , 3, e28048	3
1593	High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. <b>2014</b> , 3, e28836	70

1592	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <b>2014</b> , 3, e27560	34
1591	Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. <b>2014</b> , 13, 219	28
1590	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. <b>2014</b> , 12, 277	10
1589	Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1 T-cell subsets. <b>2014</b> , 3, e28101	4
1588	Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. <b>2014</b> , 106,	215
1587	Programmed death-1 impairs secondary effector lung CD8+ T cells during respiratory virus reinfection. <b>2014</b> , 193, 5108-17	28
1586	Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. <b>2014</b> , 74, 4042-52	94
1585	PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells. <b>2014</b> , 44, 3560-72	27
1584	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. <b>2014</b> , 5, e1568	38
1583	Myeloid cells' evasion of melanoma immunity. <b>2014</b> , 134, 2675-2677	3
1582	Current advances in T-cell-based cancer immunotherapy. <b>2014</b> , 6, 1265-78	92
1581	Antibodies to watch in 2014. <b>2014</b> , 6, 5-14	80
1580	Reversal of tumor immune inhibition using a chimeric cytokine receptor. <b>2014</b> , 22, 1211-1220	121
1579	Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. <b>2014</b> , 23, 457-67	19
1578	Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. <b>2014</b> , 193, 1828-35	45
1577	CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. <b>2014</b> , 134, 1369-1377	41
1576	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. <b>2014</b> , 14, 523-42	11
1575	The role of systemic and targeted therapies in brain metastases. <b>2014</b> , 14, 93-103	6

1574	The impact of the TIM gene family on tumor immunity and immunosuppression. <b>2014</b> , 11, 41-8	21
1573	Immune checkpoints: A therapeutic target in triple negative breast cancer. <b>2014</b> , 3, e28325	31
1572	Overcoming tumor-mediated immunosuppression. <b>2014</b> , 6, 973-88	28
1571	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. <b>2014</b> , 5, e1434	9
1570	Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. <b>2014</b> , 4, 367	24
1569	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. <b>2014</b> , 24, 743-50	440
1568	Comment on "drug discovery: turning the titanic". <b>2014</b> , 6, 229le2	7
1567	The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. <b>2014</b> , 20, 4982-4	70
1566	Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. <b>2014</b> , 12, e1001758	46
1565	Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. <b>2014</b> , 19, 937-50	7
1564	Autoimmunity as a double agent in tumor killing and cancer promotion. <b>2014</b> , 5, 116	32
1563	Does the immune system naturally protect against cancer?. <b>2014</b> , 5, 197	141
1562	Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?. <b>2014</b> , 5, 360	110
1561	Control of the immune response by pro-angiogenic factors. <b>2014</b> , 4, 70	187
1560	Promising targets and current clinical trials in metastatic squamous cell lung cancer. <b>2014</b> , 4, 320	5
1559	Experiences and expectations for glioma immunotherapeutic approaches. <b>2014</b> , 4, 355	1
1558	Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?. <b>2014</b> , 6, 1180-94	8
1557	Induction of HLA-A*33-restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH. <b>2014</b> , 2, 809-812	4



1556	B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma. <b>2014</b> , 7, 1474-1478	17
1555	HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. <b>2014</b> , 6, 1715-58	46
1554	Is vaccine research still relevant for metastatic melanoma?. <b>2014</b> , 1, 91-94	4
1553	The role of inflammation in kidney cancer. <b>2014</b> , 816, 197-234	62
1552	Evolving strategies for cancer and autoimmunity: back to the future. <b>2014</b> , 5, 154	4
1551	Oncolytic viruses as anticancer vaccines. <b>2014</b> , 4, 188	54
1550	Immunotherapy for Lung Cancer: Has it Finally Arrived?. <b>2014</b> , 4, 288	28
1549	BRAF and beyond: Tailoring strategies for the individual melanoma patient. <b>2014</b> , 13, 1	13
1548	Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy. <b>2014</b> , 4, 338	9
1547	Restoring the balance: immunotherapeutic combinations for autoimmune disease. <b>2014</b> , 7, 503-13	65
1546	Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function. <b>2014</b> , 35, 1788-97	29
1545	The MEK inhibitor trametinib for the treatment of advanced melanoma. <b>2014</b> , 2, 1341-1349	
1544	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. <b>2014</b> , 94, 13-30	56
1543	Targeted therapy for renal cell carcinoma: The next lap. <b>2014</b> , 13, 3	21
1542	Immune checkpoint inhibitors in clinical trials. <b>2014</b> , 33, 434-44	68
1541	Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. <b>2014</b> , 36, 182-6	1
1540	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. <b>2014</b> , 10, 1255-75	5
1539	Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. <b>2014</b> , 5, 176	29

1538	Treating advanced melanoma: current insights and opportunities. <b>2014</b> , 6, 349-56	26
1537	Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. <b>2014</b> , 10, e1003856	185
1536	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. <b>2014</b> , 23, 367-78	60
1535	Whole-Cell Vaccines. <b>2014</b> , 1-14	
1534	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. <b>2014</b> , 3, 443-457	7
1533	Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. <b>2014</b> , 32, 33-9	5
1532	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. <b>2014</b> , 3, 175-190	1
1531	[Immunotherapies and melanoma]. <b>2014</b> , 101 Suppl 2, S13-24	1
1530	New treatments for metastatic melanoma. <b>2014</b> , 186, 754-60	9
1529	Targeting CD8+ T-cell tolerance for cancer immunotherapy. <b>2014</b> , 6, 833-52	37
1528	[New treatment options for metastatic melanoma]. <b>2014</b> , 139, 1462-7	0
1527	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. <b>2014</b> , 14, 709-19	8
1526	Treatment strategies for clinically detectable metastatic uveal melanoma. <b>2014</b> , 168-190	
1525	Perspektiven für eine Immuntherapie beim hepatozellulären Karzinom. <b>2014</b> , 35, 286-290	
1524	CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6-8 2014, Mainz, Germany. <b>2014</b> , 10, 3090-100	
1523	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. <b>2014</b> , 6, 1017-20	9
1522	Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. <b>2014</b> , 111, 2265-70	80
1521	The adaptation model of immunity. <b>2014</b> , 6, 59-70	8

1520	The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. <b>2014</b> , 46, 384-96	12
1519	Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients. <b>2014</b> , 3, e954862	4
1518	Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8 T-cell therapy. <b>2014</b> , 3, e958951	2
1517	Breakthrough therapies in melanoma. <b>2014</b> , 10, 781-4	
1516	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <b>2014</b> , 40, 1056-64	146
1515	New Approaches in Immunotherapy for the Treatment of Lung Cancer. <b>2017</b> , 405, 1-31	6
1514	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. <b>2014</b> , 28, 2367-75	239
1513	Tumoral immune suppression by macrophages expressing fibroblast activation protein- $\beta$ and heme oxygenase-1. <b>2014</b> , 2, 121-6	91
1512	Trafficking of T cells into tumors. <b>2014</b> , 74, 7168-74	225
1511	Galectin-1 and immune suppression during radiotherapy. <b>2014</b> , 20, 6230-2	7
1510	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <b>2014</b> , 5, 5712	374
1509	Identification and characterization of bovine programmed death-ligand 2. <b>2014</b> , 58, 388-97	1
1508	Immunotherapy and lung cancer: current developments and novel targeted therapies. <b>2014</b> , 6, 1221-35	41
1507	Immunotherapy in pediatric malignancies: current status and future perspectives. <b>2014</b> , 10, 1659-78	10
1506	Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma. <b>2014</b> , 120, 808-17	23
1505	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. <b>2014</b> , 10, 1779-94	7
1504	Signals and pathways controlling regulatory T cells. <b>2014</b> , 258, 117-31	41
1503	Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. <b>2014</b> , 182, 252-7	12

1502	Transient MEK inhibitor-associated retinopathy in metastatic melanoma. <b>2014</b> , 25, 1437-1441	83
1501	Re-adapting T cells for cancer therapy: from mouse models to clinical trials. <b>2014</b> , 257, 145-64	60
1500	Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. <b>2014</b> , 23, 2965-70	348
1499	Advances in Tumor Immunology and Immunotherapy. <b>2014</b> ,	0
1498	Future agents and treatment directions in multiple myeloma. <b>2014</b> , 7, 127-41	25
1497	Exploiting the curative potential of adoptive T-cell therapy for cancer. <b>2014</b> , 257, 56-71	338
1496	Nano-Oncologicals. <b>2014</b> ,	4
1495	Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2230-2	59.2 37
1494	TCR repertoires of intratumoral T-cell subsets. <b>2014</b> , 257, 72-82	51
1493	Targeted therapy in melanoma: the era of personalized medicine. <b>2014</b> , 20, 425-430	1
1492	Therapeutic targets in subependymoma. <b>2014</b> , 277, 168-75	16
1491	Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. <b>2014</b> , 6, 577-618	5
1490	The use of endogenous T cells for adoptive transfer. <b>2014</b> , 257, 250-63	49
1489	Universes collide: combining immunotherapy with targeted therapy for cancer. <b>2014</b> , 4, 1377-86	62
1488	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <b>2014</b> , 515, 568-71	4014
1487	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <b>2014</b> , 515, 558-62	1751
1486	Astronomy: Cosmic triangles and black-hole masses. <b>2014</b> , 515, 498-9	
1485	Why is melanoma so metastatic?. <b>2014</b> , 27, 19-36	69

1484	Cancer: Antitumour immunity gets a boost. <b>2014</b> , 515, 496-8	77
1483	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <b>2014</b> , 515, 563-7	3354
1482	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <b>2014</b> , 515, 577-81	1331
1481	High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. <b>2014</b> , 29, 53-7	13
1480	Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease. <b>2014</b> , 36, 197-204	4
1479	Current management and future perspectives of metastatic renal cell carcinoma. <b>2014</b> , 21, 847-55	24
1478	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. <b>2014</b> , 25, 1536-43	433
1477	The immunogenicity of breast cancer--molecular subtypes matter. <b>2014</b> , 25, 1453-5	24
1476	Efficacy of a general practitioner training campaign for early detection of melanoma in France. <b>2014</b> , 170, 123-9	18
1475	Management of metastatic kidney cancer in the era of personalized medicine. <b>2014</b> , 51, 85-97	4
1474	Rush hour traffic: directing T cells to tumor. <b>2014</b> , 106,	
1473	Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis. <b>2014</b> , 170, 66-77	40
1472	PD-L1 expression in nonclear-cell renal cell carcinoma. <b>2014</b> , 25, 2178-2184	202
1471	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <b>2014</b> , 111, 11774-9	426
1470	Clinical impact of checkpoint inhibitors as novel cancer therapies. <b>2014</b> , 74, 1993-2013	77
1469	Intralesional immunotherapy for melanoma. <b>2014</b> , 109, 320-6	46
1468	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. <b>2014</b> , 120, 624-32	39
1467	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. <b>2014</b> , 2, 1132-41	33

1466	Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. <b>2014</b> , 3, 215-24	40
1465	Major therapeutic developments and current challenges in advanced melanoma. <b>2014</b> , 170, 36-44	18
1464	In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. <b>2014</b> , 134, 2878-90	13
1463	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <b>2014</b> , 5, 5241	573
1462	Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy. <b>2014</b> , 6, 803-5	4
1461	Evolving role of tumor antigens for future melanoma therapies. <b>2014</b> , 10, 1457-68	11
1460	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. <b>2014</b> , 28, 513-26	7
1459	Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. <b>2014</b> , 6, 226ra32	484
1458	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. <b>2014</b> , 312, 1744-53	259
1457	Dabrafenib for the treatment of melanoma. <b>2014</b> , 15, 1043-50	4
1456	[Immunotherapies and targeted therapies in medical oncology]. <b>2014</b> , 101, 31-9	2
1455	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. <b>2014</b> , 6, 254ra128	281
1454	Reversal of natural killer cell exhaustion by TIM-3 blockade. <b>2014</b> , 3, e946365	62
1453	Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. <b>2014</b> , 211, 515-27	101
1452	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <b>2014</b> , 10, 79-90	21
1451	Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. <b>2014</b> , 44, 1299-307	12
1450	Strategies for modern biomarker and drug development in oncology. <b>2014</b> , 7, 70	87
1449	A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. <b>2014</b> , 16, 1194-203	36

1448	Potential for immunotherapy in soft tissue sarcoma. <b>2014</b> , 10, 3117-24	21
1447	Local tumour ablative therapies: opportunities for maximising immune engagement and activation. <b>2014</b> , 1846, 510-23	13
1446	The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. <b>2014</b> , 1, 396-412	50
1445	Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. <b>2014</b> , 2, 27-36	69
1444	Animal models for viral infection and cell exhaustion. <b>2014</b> , 9, 492-9	4
1443	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'. <b>2014</b> , 24, 237-43	28
1442	The role of systemic therapies in the management of melanoma brain metastases. <b>2014</b> , 26, 222-9	17
1441	Renal cell carcinoma: molecular biology and targeted therapy. <b>2014</b> , 26, 321-7	41
1440	Axitinib for the treatment of advanced renal cell carcinoma. <b>2014</b> , 15, 283-97	11
1439	Where to start with systemic melanoma therapy?. <b>2014</b> , 1, 15-18	
1438	Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. <b>2014</b> , 3, e28499	51
1437	Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. <b>2014</b> , 37, 360-5	11
1436	B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. <b>2014</b> , 20, 281-9	52
1435	CAR T cells for solid tumors: armed and ready to go?. <b>2014</b> , 20, 151-5	134
1434	Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. <b>2014</b> , 3, e27588	12
1433	Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. <b>2014</b> , 3, e27589	29
1432	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. <b>2014</b> , 26, 204-14	57
1431	B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. <b>2014</b> , 9, 1036-1040	177

1430	Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. <b>2014</b> , 20, 256-61	96
1429	Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. <b>2014</b> , 9, 144-53	69
1428	Tumor-stroma crosstalk: targeting stroma in breast cancer. <b>2014</b> , 26, 551-5	37
1427	Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. <b>2014</b> , 9, 1609-17	46
1426	Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. <b>2014</b> , 38, 1715-23	117
1425	Harnessing the immune system for cancer therapy. <b>2014</b> , 26, 600-7	19
1424	Distinctive features of CD4+ T cell dysfunction in chronic viral infections. <b>2014</b> , 9, 446-51	35
1423	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. <b>2014</b> , 20, 272-80	14
1422	Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. <b>2014</b> , 20, 4390-9	30
1421	Tumor-associated antigen specific CD8 T cells in hepatocellular carcinoma - a promising target for immunotherapy. <b>2014</b> , 3, e954919	16
1420	Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. <b>2014</b> , 4, 674-87	182
1419	The immune microenvironment: a major player in human cancers. <b>2014</b> , 164, 13-26	49
1418	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. <b>2014</b> , 3, e962401	31
1417	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. <b>2014</b> , 20, 1656-65	43
1416	Adjuvant therapy for renal cell carcinoma: past, present, and future. <b>2014</b> , 19, 851-9	47
1415	Genetic evolution of T-cell resistance in the course of melanoma progression. <b>2014</b> , 20, 6593-604	106
1414	A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway. <b>2014</b> , 3, e28440	12
1413	The Cancer Research Institute 2013 Annual Symposium: Dynamics of host-tumor interaction. <b>2014</b> , 2, 105-11	



1412	Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. <b>2014</b> , 6, 237ra67	432
1411	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. <b>2014</b> , 10, 937-48	8
1410	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. <b>2014</b> , 14, 1495-513	6
1409	Genetically Modified Dendritic Cell Vaccines for Solid Tumors. <b>2014</b> , 273-282	
1408	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. <b>2014</b> , 5, 206	89
1407	Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. <b>2014</b> , 9, e89561	40
1406	Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using myeloid-derived suppressor cells as a readout of therapeutic efficacy. <b>2014</b> , 3, e945378	27
1405	Novel dendritic cell-based vaccination in late stage melanoma. <b>2014</b> , 10, 3132-8	10
1404	Discovering cancer immunotherapy targets in vivo. <b>2014</b> , 3, e28500	1
1403	Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. <b>2014</b> , 3, e29244	65
1402	PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. <b>2014</b> , 3, e29288	50
1401	Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. <b>2014</b> , 5, 74	34
1400	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. <b>2014</b> , 2, 643-54	190
1399	Detection of binding of a synthetic granzyme B-like peptide fluorescent conjugate within platelet-like structures in cancer-related peripheral blood specimens and tissue sections. <b>2014</b> , 24, 1473-9	1
1398	Structure and cancer immunotherapy of the B7 family member B7x. <b>2014</b> , 9, 1089-98	49
1397	Medical Management of Melanoma. <b>2014</b> , 651-660	
1396	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. <b>2014</b> , 29, 2021-31	10
1395	Current concepts in the diagnosis and management of cytokine release syndrome. <b>2014</b> , 124, 188-95	1520

1394	Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. <b>2014</b> , 31, 384-90	15
1393	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. <b>2014</b> , 37-51	
1392	Nasopharyngeal Carcinoma: Management Strategies. <b>2014</b> ,	1
1391	Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. <b>2014</b> , 20, 1223-34	71
1390	Extracranial oligometastatic renal cell carcinoma: current management and future directions. <b>2014</b> , 10, 761-74	22
1389	Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. <b>2014</b> , 32, 2935-7	34
1388	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <b>2014</b> , 124, 453-62	249
1387	Evaluating biomarkers in melanoma. <b>2014</b> , 4, 383	33
1386	Combination therapies for the treatment of advanced melanoma: a review of current evidence. <b>2014</b> , 2014, 307059	14
1385	The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. <b>2014</b> , 2014, 789069	29
1384	Oncolytic immunotherapy: where are we clinically?. <b>2014</b> , 2014, 862925	13
1383	Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. <b>2014</b> , 7, 1049-68	17
1382	Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". <b>2014</b> , 6, 914-33	51
1381	gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. <b>2014</b> , 2, 1035-1042	18
1380	Sarcoma immunotherapy: past approaches and future directions. <b>2014</b> , 2014, 391967	36
1379	Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. <b>2014</b> , 10, 207-17	49
1378	Immunologic treatments for precancerous lesions and uterine cervical cancer. <b>2014</b> , 33, 29	32
1377	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. <b>2014</b> , 2, 7	85

1376	T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. <b>2014</b> , 20, 1768-78	66
1375	Cancer immunoprevention--the next frontier. <b>2014</b> , 7, 1072-80	20
1374	TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. <b>2014</b> , 2, 1011-22	40
1373	Immunotherapy of hepatocellular carcinoma. <b>2014</b> , 1, 433-446	4
1372	Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. <b>2014</b> , 37, 187-91	6
1371	Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. <b>2014</b> , 9, 439-45	52
1370	Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. <b>2014</b> , 20, 29-42	15
1369	Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. <b>2014</b> , 20, 290-5	24
1368	Cutaneous melanoma. <b>2014</b> , 383, 816-27	379
1367	New drug targets in metastatic melanoma. <b>2014</b> , 232, 134-41	47
1366	A personalized view on cancer immunotherapy. <b>2014</b> , 352, 113-25	45
1365	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <b>2014</b> , 15, 297-304	49
1364	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. <b>2014</b> , 15, 69-77	441
1363	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. <b>2014</b> , 50, 1361-9	241
1362	Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. <b>2014</b> , 47, 612-7	32
1361	Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. <b>2014</b> , 15, 16-20	1
1360	Extending survival of stage IV non-small cell lung cancer. <b>2014</b> , 41, 69-92	32
1359	Targeted therapies for cutaneous melanoma. <b>2014</b> , 28, 491-505	10

1358	Castration-resistant prostate cancer: from new pathophysiology to new treatment. <b>2014</b> , 65, 289-99	94
1357	Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. <b>2014</b> , 29, 110-5	22
1356	Virus infection, inflammation and prevention of cancer. <b>2014</b> , 193, 33-58	10
1355	Personalized Health Care (PHC) in Cancer. <b>2014</b> , 23-49	
1354	Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. <b>2014</b> , 32, 31-8	25
1353	Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. <b>2014</b> , 32, 19-29	10
1352	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. <b>2014</b> , 123, 2062-5	215
1351	Genetic alterations and personalized medicine in melanoma: progress and future prospects. <b>2014</b> , 106, djt435	57
1350	The new normal: immunomodulatory agents against sepsis immune suppression. <b>2014</b> , 20, 224-33	163
1349	Adoptive immunotherapy for cancer or viruses. <b>2014</b> , 32, 189-225	201
1348	New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. <b>2014</b> , 27, 16-25	882
1347	Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. <b>2014</b> , 11, 182-4	20
1346	Phénomène d'ADCC, polymorphismes du récepteur Fc $\gamma$ R2 et conséquences en termes de développement thérapeutique ciblé <b>2014</b> , 16, 112-119	
1345	Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. <b>2014</b> , 35, 5753-62	31
1344	Potential of new therapies like anti-PD1 in kidney cancer. <b>2014</b> , 15, 137-46	31
1343	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. <b>2014</b> , 63, 215-24	81
1342	The GIST of targeted therapy for malignant melanoma. <b>2014</b> , 21, 2059-67	16
1341	Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. <b>2014</b> , 12, 36	122

1340	Immunotherapy for non-small-cell lung cancer: current approaches. <b>2014</b> , 3, 19-25	2
1339	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. <b>2014</b> , 18, R3	177
1338	New treatment strategies for HPV-positive head and neck cancer. <b>2014</b> , 271, 1861-7	45
1337	CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. <b>2014</b> , 2, 91-8	199
1336	Targeting tumour-supportive cellular machineries in anticancer drug development. <b>2014</b> , 13, 179-96	169
1335	Regulatory T cells in cancer immunotherapy. <b>2014</b> , 27, 1-7	479
1334	Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. <b>2014</b> , 89, 140-65	122
1333	Immunotherapy for solid tumors--a review for surgeons. <b>2014</b> , 187, 525-35	14
1332	Targeted therapies in gastroesophageal cancer. <b>2014</b> , 50, 1247-58	41
1331	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. <b>2014</b> , 27, 89-97	90
1330	Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. <b>2014</b> , 159, 55-72	81
1329	State of the science in cervical cancer: where we are today and where we need to go. <b>2014</b> , 120, 2282-8	34
1328	Determining the optimal dose in the development of anticancer agents. <b>2014</b> , 11, 272-81	111
1327	Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?. <b>2014</b> , 24, 125-38	11
1326	The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. <b>2014</b> , 54, 289-96	548
1325	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. <b>2014</b> , 120, 1695-701	151
1324	Cancer Immunotherapy Meets Oncology. <b>2014</b> ,	
1323	PD-L1 is a novel direct target of HIF-1 $\beta$ and its blockade under hypoxia enhanced MDSC-mediated T cell activation. <b>2014</b> , 211, 781-90	1136

1322	What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?. <b>2014</b> , 120, 1462-70	47
1321	A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. <b>2014</b> , 2, 610-5	29
1320	Effects of obesity on immune responses to renal tumors. <b>2014</b> , 59, 211-9	2
1319	Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. <b>2014</b> , 51, 228-34	35
1318	Programmed death ligand-1 expression in non-small cell lung cancer. <b>2014</b> , 94, 107-16	591
1317	Tim-3: an emerging target in the cancer immunotherapy landscape. <b>2014</b> , 2, 393-8	214
1316	"In vitro" 3D models of tumor-immune system interaction. <b>2014</b> , 79-80, 145-54	63
1315	Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. <b>2014</b> , 2, 301-20	167
1314	Lung tumours reprogram pulmonary dendritic cell immunogenicity at the microRNA level. <b>2014</b> , 135, 2868-77	22
1313	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. <b>2014</b> , 25, 968-74	53
1312	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. <b>2014</b> , 6, 459-75	76
1311	Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. <b>2014</b> , 13, 117-30	30
1310	Dendritic cell-based vaccines: clinical applications in breast cancer. <b>2014</b> , 6, 349-60	29
1309	Recent clinical advances in lung cancer management. <b>2014</b> , 32, 973-82	169
1308	Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. <b>2014</b> , 74, 2974-85	110
1307	Interaction of Immune and Cancer Cells. <b>2014</b> ,	
1306	Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. <b>2014</b> , 1102, 287-324	61
1305	Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. <b>2014</b> , 99, 123-31	12

1304	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. <b>2014</b> , 28, 993-1000	81
1303	Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. <b>2014</b> , 40, 205-14	62
1302	CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. <b>2014</b> , 20, 44-55	185
1301	Immune modulation in cancer with antibodies. <b>2014</b> , 65, 185-202	366
1300	Checkpoint blocking antibodies in cancer immunotherapy. <b>2014</b> , 588, 368-76	184
1299	Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. <b>2014</b> , 33, 4623-31	96
1298	Viruses and Human Cancer. <b>2014</b> ,	
1297	Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. <b>2014</b> , 21, 240-7	13
1296	The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. <b>2014</b> , 7, 1-17	72
1295	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. <b>2014</b> , 21, 262-71	62
1294	Do inhibitory immune receptors play a role in the etiology of autoimmune disease?. <b>2014</b> , 150, 31-42	18
1293	Beyond sipuleucel-T: immune approaches to treating prostate cancer. <b>2014</b> , 15, 115-26	11
1292	Cancer: interference identifies immune modulators. <b>2014</b> , 506, 39-40	
1291	Mitigating the toxic effects of anticancer immunotherapy. <b>2014</b> , 11, 91-9	150
1290	The immune system and response to HER2-targeted treatment in breast cancer. <b>2014</b> , 15, e58-68	171
1289	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. <b>2014</b> , 35, 51-60	380
1288	Immunotherapy for prostate cancer: recent developments and future challenges. <b>2014</b> , 33, 641-55	49
1287	In vivo discovery of immunotherapy targets in the tumour microenvironment. <b>2014</b> , 506, 52-7	159

1286	Molecularly targeted cancer therapy: some lessons from the past decade. <b>2014</b> , 35, 41-50	206
1285	CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. <b>2014</b> , 192, 224-33	15
1284	Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. <b>2014</b> , 15, 41-54	12
1283	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. <b>2014</b> , 28, 1280-8	460
1282	Biomarkers of renal cell carcinoma. <b>2014</b> , 32, 243-51	34
1281	Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. <b>2014</b> , 18, 90-7	24
1280	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <b>2014</b> , 11, 24-37	311
1279	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. <b>2014</b> , 18, 1407-20	28
1278	Immunotherapy for malignant pleural mesothelioma. Current status and future prospects. <b>2014</b> , 50, 870-5	21
1277	Recognition of tumors by the innate immune system and natural killer cells. <b>2014</b> , 122, 91-128	233
1276	Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. <b>2014</b> , 123, 678-86	207
1275	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. <b>2014</b> , 3, e22	48
1274	Immunotherapy and radiation. <b>2014</b> , 41, 702-13	7
1273	STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. <b>2014</b> , 41, 830-42	876
1272	Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. <b>2014</b> , 20, 221-32	94
1271	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. <b>2014</b> , 14, 1023-31	1
1270	Novel Technologies for Vaccine Development. <b>2014</b> ,	1
1269	The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. <b>2014</b> , 346, 945-9	246



1268	A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism. <b>2014</b> , 122, 1-2		
1267	Recent developments in the medical and surgical treatment of melanoma. <b>2014</b> , 64, 171-85		46
1266	Thérapies ciblées : quel traitement pour quel patient ?. <b>2014</b> , 6, 459-469		
1265	Melanoma: smart therapeutic strategies in immuno-oncology. <b>2014</b> , 11, 181-2		17
1264	Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. <b>2014</b> , 33, 1109-24		60
1263	[Pharmacotherapy of solid tumors. New hopes and frustrations]. <b>2014</b> , 55, 1220-7		1
1262	Current management of advanced melanoma: a transformed landscape. <b>2014</b> , 84, 612-7		11
1261	Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. <b>2014</b> , 2, 15-8		82
1260	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1867-76	59.2	1403
1259	New Targets and New Drug Development in Colorectal Cancer. <b>2014</b> , 10, 288-295		1
1258	Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice. <b>2014</b> , 80, 111-20		1
1257	Renal cell carcinoma. <b>2014</b> , 349, g4797		311
1256	Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. <b>2014</b> , 16, 400		22
1255	Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma—an intergroup study of cancer and leukemia Group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <b>2014</b> , 32, 3771-8		83
1254	Insights into the mechanism of organ-specific cancer metastasis. <b>2014</b> , 4, 1262-4		6
1253	Immune-based therapies for childhood cancer. <b>2014</b> , 11, 693-703		67
1252	Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. <b>2014</b> , 41, 559-75		3
1251	CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. <b>2014</b> , 22, 1949-59		212

1250	Current perspectives on immunotherapy. <b>2014</b> , 41 Suppl 5, S14-29	23
1249	Future approaches in immunotherapy. <b>2014</b> , 41 Suppl 5, S30-40	21
1248	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. <b>2014</b> , 74, 632; discussion 635	12
1247	Impact of sepsis on CD4 T cell immunity. <b>2014</b> , 96, 767-77	98
1246	Immunotherapy for brain cancer: recent progress and future promise. <b>2014</b> , 20, 3651-9	67
1245	Cancer immunotherapy: hype or ripe? [corrected]. <b>2014</b> , 44, 318-20	2
1244	Novel agents in development for advanced non-small cell lung cancer. <b>2014</b> , 6, 240-53	26
1243	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. <b>2014</b> , 25, 2433-2442	98
1242	The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. <b>2014</b> , 182, 170-81	70
1241	Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. <b>2014</b> , 21, R445-60	38
1240	New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. <b>2014</b> , 20, 6233-41	16
1239	Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. <b>2014</b> , 26, 559-77	41
1238	Immune approaches to the treatment of breast cancer, around the corner?. <b>2014</b> , 16, 204	33
1237	Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. <b>2014</b> , 33, 5053-64	37
1236	Immune checkpoint inhibitors in NSCLC. <b>2014</b> , 15, 658-69	56
1235	Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. <b>2014</b> , 2, 137-48	16
1234	Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals. <b>2014</b> , 63, 1047-60	12
1233	Immunotherapy for primary brain tumors: no longer a matter of privilege. <b>2014</b> , 20, 5620-9	74

1232	Emerging immunotherapy strategies in breast cancer. <b>2014</b> , 6, 195-209	22
1231	The translation of cancer genomics: time for a revolution in clinical cancer care. <b>2014</b> , 6, 22	10
1230	The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. <b>2014</b> , 182, 219-29	24
1229	Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. <b>2014</b> , 123, 2172-80	19
1228	Covalent small molecule inhibitors of Ca(2+)-bound S100B. <b>2014</b> , 53, 6628-40	26
1227	Mechanisms of hypoxia-mediated immune escape in cancer. <b>2014</b> , 74, 7185-90	119
1226	The path to reactivation of antitumor immunity and checkpoint immunotherapy. <b>2014</b> , 2, 926-36	22
1225	Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. <b>2014</b> , 28, 1759-62	13
1224	Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. <b>2014</b> , 2, 831-8	226
1223	Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. <b>2014</b> , 354, 12-20	74
1222	Immunotherapy advances for glioblastoma. <b>2014</b> , 16, 1441-58	136
1221	The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. <b>2014</b> , 2, 187-93	156
1220	PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. <b>2014</b> , 111, 1391-9	68
1219	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. <b>2014</b> , 23, 305-15	18
1218	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <b>2014</b> , 384, 1109-17	1340
1217	Acquired and intrinsic resistance in cancer immunotherapy. <b>2014</b> , 8, 1132-9	133
1216	Vaccine therapies for patients with glioblastoma. <b>2014</b> , 119, 531-46	24
1215	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <b>2014</b> , 14, 1173-87	23

1214	Tracking cellular and immune therapies in cancer. <b>2014</b> , 124, 257-96	24
1213	Immune modulation for cancer therapy. <b>2014</b> , 111, 2214-9	110
1212	Regulated cell death and inflammation: an auto-amplification loop causes organ failure. <b>2014</b> , 14, 759-67	291
1211	Radionuclide imaging of drug delivery for patient selection in targeted therapy. <b>2014</b> , 11, 175-85	7
1210	Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. <b>2014</b> , 53, 1-9	38
1209	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <b>2014</b> , 14, 768-74	191
1208	Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. <b>2014</b> , 20, 331-43	45
1207	Optimal management of skin cancer in immunosuppressed patients. <b>2014</b> , 15, 339-56	26
1206	Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?. <b>2014</b> , 63, 1081-91	39
1205	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. <b>2014</b> , 8, 1140-58	39
1204	Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. <b>2014</b> , 2, 598-605	126
1203	Adjuvant interferon in melanoma: is duration of therapy important?. <b>2014</b> , 32, 171-3	5
1202	New strategies in lung cancer: translating immunotherapy into clinical practice. <b>2014</b> , 20, 1067-73	36
1201	A Notch for noncoding RNA in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1950-1	59.2 3
1200	Therapy: This time it's personal. <b>2014</b> , 509, S52-4	10
1199	PTPN2 restrains CD8+ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. <b>2014</b> , 53, 105-14	30
1198	Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. <b>2014</b> , 2, 436-47	147
1197	Vers une classification moléculaire du cancer bronchique. <b>2014</b> , 6, 89-91	

1196	Non-small-cell lung cancers: a heterogeneous set of diseases. <b>2014</b> , 14, 535-46	934
1195	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. <b>2014</b> , 14, 955-67	20
1194	Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. <b>2014</b> , 193, 1525-30	111
1193	A cancer model for the angiogenic switch. <b>2014</b> , 360, 21-33	14
1192	Mise au point 2014 du cancer bronchique non ĩpetites cellules (en dehors du dĩstage). <b>2014</b> , 95, 708-712	
1191	Antibodies in Cancer Treatment: Early Clinical Development. <b>2014</b> , 787-822	
1190	Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials. <b>2014</b> , 735-786	
1189	Radical irradiation of extracranial oligometastases. <b>2014</b> , 32, 2902-12	66
1188	p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. <b>2014</b> , 20, 4459-70	17
1187	Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. <b>2014</b> , 166, 326-35	39
1186	Programmed cell death ligand 1 expression in osteosarcoma. <b>2014</b> , 2, 690-698	135
1185	Management of melanoma. <b>2014</b> , 111, 149-62	50
1184	Targeting cancer-derived adenosine: new therapeutic approaches. <b>2014</b> , 4, 879-88	199
1183	Systemic treatment for BRAF-mutant melanoma: where do we go next?. <b>2014</b> , 15, e371-81	114
1182	Role of lymphatic vasculature in regional and distant metastases. <b>2014</b> , 95, 46-52	59
1181	Therapeutic antibodies in breast cancer. <b>2014</b> , 41, 576-88	3
1180	Nivolumab: a review of its use in patients with malignant melanoma. <b>2014</b> , 74, 1233-9	59
1179	Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. <b>2014</b> , 88, 2508-18	43

1178	New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. <b>2014</b> , 20, 5349-58	55
1177	Immunotherapy: Chemical tricks. <b>2014</b> , 513, S10-1	3
1176	Melanocytic Lesions. <b>2014</b> ,	1
1175	Highlights from the latest articles in lung cancer personalized medicine. <b>2014</b> , 11, 377-379	
1174	The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. <b>2014</b> , 193, 3835-41	127
1173	The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. <b>2014</b> , 120, 3142-53	58
1172	Molecular insights into the development of T cell-based immunotherapy for prostate cancer. <b>2014</b> , 10, 1547-57	6
1171	Stromal reengineering to treat pancreas cancer. <b>2014</b> , 35, 1451-60	84
1170	Primary mediastinal large B-cell lymphoma. <b>2014</b> , 9, 273-83	23
1169	Strategies to eliminate HBV infection. <b>2014</b> , 9, 565-585	41
1168	Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment. <b>2014</b> , 11, 630-2	121
1167	Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. <b>2014</b> , 31, 166	38
1166	Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. <b>2014</b> , 2, 11	139
1165	Opportunistic infections in patients treated with immunotherapy for cancer. <b>2014</b> , 2, 19	78
1164	Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. <b>2014</b> , 12, 132	50
1163	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. <b>2014</b> , 12, 245	9
1162	The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. <b>2014</b> , 2,	77
1161	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. <b>2014</b> , 2, 30	21

1160	Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. <b>2014</b> , 32, 3659-66	59
1159	Shaping of an effective immune microenvironment to and by cancer cells. <b>2014</b> , 63, 991-7	25
1158	Fc Receptors. <b>2014</b> ,	8
1157	Nivolumab: promising survival signal coupled with limited toxicity raises expectations. <b>2014</b> , 32, 986-8	38
1156	Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. <b>2014</b> , 74, 5458-68	704
1155	Indications and options for systemic therapy in melanoma. <b>2014</b> , 94, 1049-58, viii	10
1154	Dendritic cell-targeted vaccines--hope or hype?. <b>2014</b> , 14, 705-11	149
1153	Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins. <b>2014</b> , 24, 356-63	1
1152	PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. <b>2014</b> , 74, 1045-55	141
1151	[Drug reactions caused by chemotherapy agents]. <b>2014</b> , 65, 443-9	4
1150	Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3+ regulatory T cell suppresses T cell response via membrane-bound TGF- $\beta$ . <b>2014</b> , 92, 539-50	27
1149	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. <b>2014</b> , 92, 709-22	64
1148	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. <b>2014</b> , 92, 697-707	47
1147	PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. <b>2014</b> , 63, 395-406	111
1146	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <b>2014</b> , 63, 449-58	207
1145	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. <b>2014</b> , 63, 545-57	76
1144	Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. <b>2014</b> , 63, 615-26	22
1143	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. <b>2014</b> , 63, 959-67	60

1142	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. <b>2014</b> , 140, 1615-24	67
1141	T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. <b>2014</b> , 145, 605-14	19
1140	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. <b>2014</b> , 146, 15-24	375
1139	PD-L1 expression in triple-negative breast cancer. <b>2014</b> , 2, 361-70	698
1138	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. <b>2014</b> , 2, 14	88
1137	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. <b>2014</b> , 2, 3	371
1136	Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. <b>2014</b> , 2, 9	10
1135	Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. <b>2014</b> , 21, 3142-50	80
1134	Biology of breast cancer during pregnancy using genomic profiling. <b>2014</b> , 21, 545-54	48
1133	PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. <b>2014</b> , 2, 320-31	109
1132	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. <b>2014</b> , 63, 1769-81	202
1131	Monoclonal antibodies as therapeutics in human malignancies. <b>2014</b> , 10, 609-36	18
1130	Targeting the tumor microenvironment with interferon- $\beta$ bridges innate and adaptive immune responses. <b>2014</b> , 25, 37-48	186
1129	Immunotherapy for lung cancer: ongoing clinical trials. <b>2014</b> , 10, 91-105	21
1128	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. <b>2014</b> , 232, 199-209	882
1127	Adoptive immunotherapy for cancer. <b>2014</b> , 257, 14-38	100
1126	Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. <b>2014</b> , 53, 883-94	41
1125	Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. <b>2014</b> , 14, 1259-70	17



1124	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. <b>2014</b> , 32, 2248-54	158
1123	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. <b>2014</b> , 20, 5064-74	1661
1122	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. <b>2014</b> , 25, 1935-1940	428
1121	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. <b>2014</b> , 20, 4251-61	55
1120	Immunologic strategies for HIV-1 remission and eradication. <b>2014</b> , 345, 169-74	163
1119	Therapeutic vaccines for cancer: an overview of clinical trials. <b>2014</b> , 11, 509-24	522
1118	2014 update on non-small cell lung cancer (excluding diagnosis). <b>2014</b> , 95, 721-5	8
1117	Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. <b>2014</b> , 59, 279-86	30
1116	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. <b>2014</b> , 74, 3652-8	178
1115	What is the role of chemotherapy in the treatment of melanoma?. <b>2014</b> , 15, 321-35	18
1114	Tumor antigen discovery through translation of the cancer genome. <b>2014</b> , 58, 292-9	8
1113	Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. <b>2014</b> , 31, 960	16
1112	Monoklonale Antikörper in der Onkologie. <b>2014</b> , 29, 112-118	
1111	Multi-specific antibodies for cancer immunotherapy. <b>2014</b> , 28, 331-43	14
1110	A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). <b>2014</b> , 12, 108	55
1109	Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. <b>2014</b> , 12, 61	45
1108	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. <b>2014</b> , 12, 97	58
1107	Engineering vaccines and niches for immune modulation. <b>2014</b> , 10, 1728-40	37

1106	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. <b>2014</b> , 10, 1065-80	8
1105	Immunologic and clinical effects of targeting PD-1 in lung cancer. <b>2014</b> , 96, 214-23	62
1104	Translational research in oncology--10 years of progress and future prospects. <b>2014</b> , 11, 649-62	51
1103	Understanding lung cancer molecular subtypes. <b>2014</b> , 11, 441-453	1
1102	Melanoma: immune checkpoint blockade story gets better. <b>2014</b> , 384, 1078-9	9
1101	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <b>2014</b> , 32, 1020-30	1684
1100	Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. <b>2014</b> , 21, 371-81	302
1099	VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. <b>2014</b> , 2, 510-7	144
1098	Lambrolizumab induced central nervous system (CNS) toxicity. <b>2014</b> , 344, 229-31	52
1097	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. <b>2014</b> , 20, 2773-82	337
1096	Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function. <b>2014</b> , 210, 1090-9	13
1095	Tumor-Induced Immune Suppression. <b>2014</b> ,	1
1094	Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. <b>2014</b> , 134, 1823-34	15
1093	Castration-resistant prostate cancer: latest evidence and therapeutic implications. <b>2014</b> , 6, 167-79	55
1092	Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. <b>2014</b> , 190, 560-71	71
1091	Immunological off-target effects of standard treatments in gastrointestinal cancers. <b>2014</b> , 25, 24-32	37
1090	Cyclin-dependent kinases as therapeutic targets in melanoma. <b>2014</b> , 27, 351-65	18
1089	In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. <b>2014</b> , 2, 846-56	402

1088	The targeting of immunosuppressive mechanisms in hematological malignancies. <b>2014</b> , 28, 1784-92	64
1087	RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. <b>2014</b> , 211, 943-59	182
1086	Pathology in drug discovery and development. <b>2014</b> , 232, 99-102	6
1085	Self-reactive T cells: suppressing the suppressors. <b>2014</b> , 63, 313-9	7
1084	Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. <b>2014</b> , 41, 235-51	104
1083	Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death. <b>2014</b> , 47, 1078-90	23
1082	Immunotherapy in the treatment of non-small cell lung cancer. <b>2014</b> , 85, 101-9	95
1081	Commentary: Molecular testing in melanoma. <b>2014</b> , 70, 863-70	4
1080	[Immunotherapy in epithelial ovarian carcinoma: hope and reality]. <b>2014</b> , 43, 198-210	1
1079	Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?. <b>2014</b> , 41, 126-32	40
1078	Minimal changes in the systemic immune response after nephrectomy of localized renal masses. <b>2014</b> , 32, 589-600	15
1077	Merkel cell carcinoma - recent advances in the biology, diagnostics and treatment. <b>2014</b> , 53, 536-46	18
1076	Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. <b>2014</b> , 88, 986-97	112
1075	The state of the art in non-small cell lung cancer immunotherapy. <b>2014</b> , 26, 26-35	7
1074	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. <b>2014</b> , 50, 627-32	161
1073	Is cancer vaccination feasible at older age?. <b>2014</b> , 54, 138-44	6
1072	Biomarkers for immune checkpoint inhibitors--authors' reply. <b>2014</b> , 15, e1-2	3
1071	Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. <b>2014</b> , 40, 121-7	113

1070	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. <b>2014</b> , 40, 513-22	116
1069	Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. <b>2014</b> , 89, 520-35	38
1068	Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. <b>2014</b> , 35, 290-8	77
1067	Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. <b>2014</b> , 2, 741-55	93
1066	Cellular immunotherapy strategies for Ewing sarcoma. <b>2014</b> , 6, 611-21	7
1065	VISTA is an immune checkpoint molecule for human T cells. <b>2014</b> , 74, 1924-32	272
1064	Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. <b>2014</b> , 2, 410-22	236
1063	Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. <b>2014</b> , 20, 3446-57	236
1062	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <b>2014</b> , 63, 407-18	71
1061	Targeting the PD-1 pathway: a promising future for the treatment of melanoma. <b>2014</b> , 306, 511-9	50
1060	VISTA Regulates the Development of Protective Antitumor Immunity. <b>2014</b> , 74, 1933-44	267
1059	Immunotherapy for non-small-cell lung cancer. <b>2014</b> , 14, 1061-4	4
1058	Updates on immunotherapy in non-small cell lung cancer. <b>2014</b> , 14, 411-8	2
1057	Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. <b>2014</b> , 8, 587-96	21
1056	Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. <b>2014</b> , 53, 2286-8	50
1055	Advances in therapy for pediatric sarcomas. <b>2014</b> , 16, 395	20
1054	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. <b>2014</b> , 25, 590-604	273
1053	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <b>2014</b> , 14, 1007-17	7

1052	Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. <b>2014</b> , 2, 127-32	104
1051	A review of novel therapies for melanoma. <b>2014</b> , 15, 323-37	44
1050	Eph receptor A10 has a potential as a target for a prostate cancer therapy. <b>2014</b> , 450, 545-9	18
1049	Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: a comprehensive review. <b>2014</b> , 54, 112-7	33
1048	Understanding the biology of melanoma and therapeutic implications. <b>2014</b> , 28, 437-53	27
1047	Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. <b>2014</b> , 24, 3403-6	41
1046	State of melanoma: an historic overview of a field in transition. <b>2014</b> , 28, 415-35	25
1045	An (only) partially established paradigm of drug development of targeted therapies. <b>2014</b> , 50, 2037-9	6
1044	Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. <b>2014</b> , 50, 2040-9	86
1043	Immune checkpoint blockade. <b>2014</b> , 28, 585-600	57
1042	Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. <b>2014</b> , 89, 504-19	63
1041	Role of immunotherapy in castration-resistant prostate cancer (CRPC). <b>2014</b> , 113, 367-75	3
1040	Cell-death-associated molecular patterns as determinants of cancer immunogenicity. <b>2014</b> , 20, 1098-116	31
1039	Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. <b>2014</b> , 53, 113-8	14
1038	Milestones in the staging, classification, and biology of Merkel cell carcinoma. <b>2014</b> , 12, 1255-62	23
1037	New Therapies in Hormone Relapsed Disease. <b>2014</b> , 265-286	
1036	Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. <b>2014</b> , 12, O8	17
1035	Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821. <b>2014</b> , 62, 638-43	18

1034	Systemic and targeted therapies for early-stage lung cancer. <b>2014</b> , 21, 21-31	17
1033	PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. <b>2014</b> , 21, 231-7	104
1032	Somatic Genome Alterations in Human Lung Cancers. <b>2014</b> , 67-89	1
1031	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. <b>2014</b> , 123, 717-24	48
1030	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. <b>2014</b> , 123, 1412-21	59
1029	Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <b>2014</b> , 1, 14004	28
1028	Pazopanib for the treatment of advanced renal cell cancer. <b>2014</b> , 2, 605-616	3
1027	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. <b>2014</b> , 8, 1461-1469	36
1026	[Intratumoral immune microenvironment and survival: the immunoscore]. <b>2014</b> , 30, 439-44	15
1025	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. <b>2014</b> , 390-405	
1024	[Immuno-Oncology therapeutic principles in lung and renal cell carcinoma]. <b>2014</b> , 37 Suppl 4, 10-3	
1023	BRAFV600E-mutant melanoma presenting with cardiac involvement. <b>2014</b> , 12, 611-5	1
1022	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. <b>2014</b> , 12, 1629-49	12
1021	Emerging targeted therapies for melanoma treatment (review). <b>2014</b> , 45, 516-24	37
1020	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <b>2014</b> , 2,	7
1019	Programmed Death-1: therapeutischer Erfolg nach über 100 Jahren Krebsimmuntherapie. <b>2014</b> , 126, 2318-2320	9
1018	Combination therapies in advanced melanoma. <b>2014</b> , 1, 47-56	1
1017	How anti-PD1 treatments are changing the management of melanoma. <b>2014</b> , 1, 165-172	3

1016	Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers. <b>2014</b> , 60, 2121-4	4
1015	Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. <b>2014</b> ,	1
1014	Reprogramming immune responses via microRNA modulation. <b>2013</b> , 1,	3
1013	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. <b>2015</b> , 23, 541-9	138
1012	Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. <b>2015</b> , 5, 392-404	46
1011	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <b>2015</b> , 10, 985-9	208
1010	Income-associated discrepancies in melanoma survival. <b>2015</b> , 4, 143-147	2
1009	[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures]. <b>2015</b> , 46, 481-5	5
1008	Targeting immune checkpoints in melanoma: an update. <b>2015</b> , 2, 339-352	1
1007	[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]. <b>2015</b> , 46, 467-72	1
1006	Expression of immune checkpoint molecules in endometrial carcinoma. <b>2015</b> , 10, 1947-1952	26
1005	Gene therapy: progress and predictions. <b>2015</b> , 282, 20143003	88
1004	Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. <b>2015</b> , 10, 1079-1086	11
1003	Combination immunotherapy with CTLA-4 and PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. <b>2015</b> , 3, 21	122
1002	[Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?]. <b>2015</b> , 46, 473-80	
1001	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. <b>2015</b> , 10, 1685-93	38
1000	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <b>2015</b> , 10, 1726-35	155
999	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. <b>2015</b> , 46, 28-36	60

998	Associations among pretreatment tumor necrosis and the expression of HIF-1 $\alpha$ and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. <b>2015</b> , 51, 1004-1010	47
997	2015 Guidance on cancer immunotherapy development in early-phase clinical studies. <b>2015</b> , 106, 1761-71	11
996	Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. <b>2015</b> , 106, 505-11	28
995	Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. <b>2015</b> , 106, 672-86	50
994	Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. <b>2015</b> , 106, 1659-68	48
993	New clinical advances in immunotherapy for the treatment of solid tumours. <b>2015</b> , 145, 182-201	26
992	Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. <b>2015</b> , 28, 490-500	93
991	Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. <b>2015</b> , 20, 199-208	3
990	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <b>2015</b> , 106, 945-50	61
989	Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. <b>2015</b> , 106, 1493-8	5
988	Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. <b>2015</b> , 106, 1750-60	35
987	Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. <b>2015</b> , 10, 577-85	96
986	Normal Lymphocytes and Non-Neoplastic Lymphocyte Disorders. <b>2015</b> , 278-302	
985	Ectopic expression of B and T lymphocyte attenuator in gastric cancer: a potential independent prognostic factor in patients with gastric cancer. <b>2015</b> , 11, 658-64	10
984	Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response. <b>2015</b> , 5, 17695	9
983	[Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint]. <b>2015</b> , 135, 663-9	
982	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. <b>2015</b> , 5, 13110	246
981	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <b>2015</b> , 10, 974-84	86



980 Principles of Targeted Immunotherapy. **2015**, 27-38

979 Acute Myeloid Leukemia. **2015**, 89-100 1

978 The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. **2015**, 126, 1203-13 71

977 Cell-specific PD-L1 expression in DLBCL. **2015**, 126, 2171-2 10

976 ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. **2015**, 7, 754-69 30

975 A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. **2015**, 7, 450-63 28

974 Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. **2015**, 3, 45 8

973 Case studies of monoclonal antibodies for cancer therapy: technology drives clinical development. **2015**, 156-165

972 Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. **2015**, 5, 12298 43

971 Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. **2015**, 34, 2042-58 69

970 Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database. **2015**, 10, 1020-6 29

969 T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in lymphoid mice. **2015**, 8, 1401-12 5

968 Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling. **2014**, 4, 4984 7

967 FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. **2015**, 1, 15049 29

966 Understanding Immune Checkpoint Inhibitors for Effective Patient Care. **2015**, 19, 709-17 15

965 The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. **2015**, 34, 2219-36 138

964 A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. **2015**, 9, 35-43 4

963 Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. **2015**, 7, 15-8 42

962	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. <b>2015</b> , 1,	78
961	?????????????. <b>2015</b> , 12, 30-32	
960	Current and emerging therapies for bone metastatic castration-resistant prostate cancer. <b>2015</b> , 22, 109-20	33
959	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. <b>2015</b> , 10, 1458-67	43
958	Emerging immunotherapies for bladder cancer. <b>2015</b> , 27, 191-200	21
957	Radiation with immunotherapy: an emerging combination for cancer treatment. <b>2015</b> , 4, 331-338	5
956	PD-1-Blockade zeigt therapeutische Aktivität <b>2015</b> , 18, 34-36	
955	Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer. <b>2015</b> , 145, 264-268	
954	PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. <b>2015</b> , 10, 189	56
953	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. <b>2015</b> , 4, 365-375	1
952	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. <b>2015</b> , 13, 319	21
951	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. <b>2015</b> , 34, 310-9	8
950	Principles of immunology and its nuances in the central nervous system. <b>2015</b> , 17 Suppl 7, vii3-vii8	23
949	Targeting the immune system: a new horizon of cancer therapies. <b>2015</b> , 2, 10-12	1
948	An der Schwelle zu einem neuen Zeitalter. <b>2015</b> , 18, 96-97	
947	Primary pulmonary melanoma: a report of two cases. <b>2015</b> , 13, 274	9
946	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. <b>2015</b> , 121, 2230-6	18
945	Present and future therapies of hepatitis B: From discovery to cure. <b>2015</b> , 62, 1893-908	211

944	CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy. <b>2015</b> , 3, P53	78
943	Targeted Therapy for Cancer in the Genomic Era. <b>2015</b> , 21, 294-8	34
942	Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. <b>2015</b> , 28, 442-52	13
941	Molecular-Targeted Therapy For Malignant Mesothelioma. <b>2015</b> , 2, 237399751560040	3
940	What's new in melanoma? Combination!. <b>2015</b> , 13, 213	33
939	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. <b>2015</b> , 13, 247	45
938	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <b>2015</b> , 13, 351	47
937	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. <b>2015</b> , 13, 374	11
936	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. <b>2015</b> , 17, 124	151
935	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. <b>2015</b> , 7, 58	15
934	Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a case report. <b>2015</b> , 9, 114	
933	A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. <b>2015</b> , 4, 186	7
932	Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. <b>2015</b> , 4, 1180-9	107
931	Inhibitory receptors as targets for cancer immunotherapy. <b>2015</b> , 45, 1892-905	84
930	Treatment for metastatic melanoma: a new and evolving era. <b>2015</b> , 69, 273-80	2
929	Immune checkpoint inhibitor therapy associated hypophysitis. <b>2015</b> , 8, 21-8	31
928	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. <b>2015</b> , 9, 31-8	19
927	B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects. <b>2015</b> , 101, 549-54	5

926	Case of respiratory discomfort due to myositis after administration of nivolumab. <b>2015</b> , 42, 1008-9	57
925	Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. <b>2015</b> , 38, 119-25	56
924	RAC1 P29S regulates PD-L1 expression in melanoma. <b>2015</b> , 28, 590-8	44
923	Recent advances in antibody-based therapies for Hodgkin Lymphoma. <b>2015</b> , 171, 171-178	4
922	Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. <b>2015</b> , 45, 696-701	18
921	Immunotherapy for Advanced Lung Cancer. <b>2015</b> , 21, 383-91	6
920	PERIOPERATIVE PROGRAMMED DEATH 1 EXPRESSION ON CD4+ T CELLS PREDICTS THE INCIDENCE OF POSTOPERATIVE INFECTIOUS COMPLICATIONS. <b>2015</b> , 44, 323-9	4
919	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. <b>2015</b> , 27, 384-91	15
918	Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. <b>2015</b> , 62, 1317-25	11
917	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. <b>2015</b> , 127, 11926-11930	8
916	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. <b>2015</b> , 54, 11760-4	175
915	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. <b>2015</b> , 137, 2083-92	14
914	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. <b>2015</b> , 35, 963-76	140
913	Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. <b>2015</b> , 46, 55-62	10
912	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <b>2015</b> , 27, 482-8	24
911	Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. <b>2015</b> , 38, 285-91	27
910	A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. <b>2015</b> , 25, 265-8	96
909	Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. <b>2015</b> , 25, 503-9	49

908	Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. <b>2015</b> , 38, 422-30	58
907	T-cell checkpoint inhibitors in metastatic renal cell carcinoma. <b>2015</b> , 25, 411-5	7
906	Immunotherapies for bladder cancer: a new hope. <b>2015</b> , 25, 586-96	13
905	Management of Small Cell Lung Cancer: Progress and Updates. <b>2015</b> , 21, 425-33	18
904	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. <b>2015</b> , 29, 1911-5	10
903	Immunonkologisches Therapieprinzip beim Lungen- und Nierenzellkarzinom. <b>2015</b> , 3, 91-92	
902	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. <b>2015</b> , e291-7	4
901	Prognostic and predictive value of PDL1 expression in breast cancer. <b>2015</b> , 6, 5449-64	313
900	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <b>2015</b> , 125, 3384-91	815
899	Immune Checkpoints Inhibitors: A Single Antiviral and Anticancer Magic Bullet. <b>2015</b> , 02,	
898	Targeting PD-1/PD-L1 in lung cancer: current perspectives. <b>2015</b> , 6, 55-70	9
897	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. <b>2015</b> , 7, 93-103	7
896	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. <b>2015</b> , 6, 1320-30	6
895	Adoptive T cell immunotherapy for cancer. <b>2015</b> , 6, e0004	131
894	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <b>2015</b> , 125, 3413-21	370
893	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. <b>2015</b> , 15, 58-65	11
892	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. <b>2015</b> , 5,	
891	Immunosuppressive Microenvironment in Head and Neck Cancer. <b>2015</b> ,	1

890	Cancer immunotherapy: harnessing the immune system to battle cancer. <b>2015</b> , 125, 3335-7	597
889	Nivolumab in the treatment of malignant melanoma: review of the literature. <b>2015</b> , 8, 2045-51	15
888	The anaplastic lymphoma kinase as an oncogene in solid tumors. <b>2015</b> , 7, 269-82	5
887	Immunoterapia genética con células dendríticas para el tratamiento del cáncer. <b>2015</b> , 38, 279-287	
886	Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond. <b>2015</b> , e299-309	16
885	Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. <b>2015</b> , 4, 75-82	15
884	PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. <b>2015</b> , 6, 234-42	187
883	Therapeutic Innovations in Ovarian Cancer Treatment: The New England Perspective. <b>2015</b> , 05,	
882	Impact of intraoperative blood loss on long-term survival after lung cancer resection. <b>2015</b> , 21, 18-23	15
881	New developments in the management of advanced melanoma - role of pembrolizumab. <b>2015</b> , 8, 2535-43	13
880	Therapeutic cancer vaccines. <b>2015</b> , 125, 3401-12	367
879	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <b>2015</b> , 7, 2397-414	51
878	New and promising strategies in the management of bladder cancer. <b>2015</b> , 105-12	14
877	Immunotherapeutic approaches in prostate cancer: combinations and clinical integration. <b>2015</b> , e275-83	2
876	Merkel cell carcinoma: emerging biology, current approaches, and future directions. <b>2015</b> , e519-26	46
875	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. <b>2015</b> , 2, 8-14	
874	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. <b>2015</b> , 3, 420-8	14
873	Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. <b>2015</b> , 3, 448-66	16

872	Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer. <b>2015</b> , 3, 1004-18	23
871	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. <b>2015</b> , 3, 662-85	176
870	Establishing the pig as a large animal model for vaccine development against human cancer. <b>2015</b> , 6, 286	12
869	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. <b>2015</b> , 6, 258	9
868	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. <b>2015</b> , 6, 271	32
867	Inhibitory Receptors Beyond T Cell Exhaustion. <b>2015</b> , 6, 310	139
866	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. <b>2015</b> , 6, 505	71
865	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <b>2015</b> , 6, 516	51
864	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <b>2015</b> , 6, 582	44
863	4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. <b>2015</b> , 5, 117	153
862	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <b>2015</b> , 5, 152	24
861	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. <b>2015</b> , 6, 14209-19	156
860	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. <b>2015</b> , 8, 929-37	21
859	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. <b>2015</b> , 4, 79-89	14
858	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. <b>2015</b> , 7, 5889-901	15
857	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <b>2015</b> , 6, 4704-16	92
856	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. <b>2015</b> , 6, 7-17	48
855	Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. <b>2015</b> , 8, 1451-7	24

854	Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2R $\beta$ . <b>2015</b> , 10, e0116723	23
853	Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. <b>2015</b> , 10, e0118564	155
852	Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. <b>2015</b> , 10, e0119483	31
851	Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF- $\kappa$ B. <b>2015</b> , 10, e0123410	145
850	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. <b>2015</b> , 10, e0142656	138
849	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <b>2015</b> , 10, e0130142	339
848	B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. <b>2015</b> , 10, e0135528	48
847	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. <b>2015</b> , 10, e0136023	167
846	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. <b>2015</b> , 10, e0139073	66
845	Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. <b>2015</b> , 10, e0143370	28
844	Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo. <b>2015</b> , 10, e0144375	20
843	Selective Loss of Early Differentiated, Highly Functional PD1 <sup>high</sup> CD4 T Cells with HIV Progression. <b>2015</b> , 10, e0144767	13
842	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <b>2015</b> , 8, 2949-57	6
841	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. <b>2015</b> , 2015, 158038	42
840	PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. <b>2015</b> , 2015, 737389	61
839	Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. <b>2015</b> , 2015, 547460	35
838	Immunotherapy for Bone and Soft Tissue Sarcomas. <b>2015</b> , 2015, 820813	15
837	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. <b>2015</b> , 2015, 191832	40



836	Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. <b>2015</b> , 2015, 968212	10
835	Clinical Development of Immune Checkpoint Inhibitors. <b>2015</b> , 2015, 605478	46
834	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. <b>2015</b> , 2015, 865101	13
833	Sepsis: From Pathophysiology to Individualized Patient Care. <b>2015</b> , 2015, 510436	39
832	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. <b>2015</b> , 2015, 367354	42
831	Immunotherapy in Tumors. <b>2015</b> , 112, 809-15	25
830	Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. <b>2015</b> , 2015, 341430	34
829	Adverse events of monoclonal antibodies used for cancer therapy. <b>2015</b> , 2015, 428169	45
828	Human Tumor Antigens and Cancer Immunotherapy. <b>2015</b> , 2015, 948501	130
827	From mice to humans: developments in cancer immunoediting. <b>2015</b> , 125, 3338-46	188
826	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. <b>2015</b> , 34, 313-21	26
825	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. <b>2015</b> , 6, 12890-908	80
824	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. <b>2015</b> , 30, 48-57	2
823	Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. <b>2015</b> , e222-7	1
822	Monoclonal Antibodies for the Treatment of Cancer. <b>2015</b> , 683-694.e3	
821	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <b>2015</b> , 6, 13506-19	87
820	Managing immune checkpoint-blocking antibody side effects. <b>2015</b> , 76-83	271
819	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. <b>2015</b> , 7, 2449-58	26

818 Cancer and the Cellular Immune Response. **2015**, 695-708.e2

817 Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. **2015**, 6, 36041-52 71

816 LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. **2015**, 6, 27359-77 151

815 Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. **2015**, 6, 2496-508 14

814 Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era. **2014**, 7, 33-43 3

813 IL-27 induces the expression of IDO and PD-L1 in human cancer cells. **2015**, 6, 43267-80 86

812 Novel immunological strategies for HIV-1 eradication. **2015**, 1, 232-236 4

811 Emerging Drug Combination Approaches in Melanoma Therapy. **2015**,

810 Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. **2015**, 10, 426-30 125

809 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*, **2015**, 372, 2509-20 59.2 5560

808 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2015**, 373, 123-35 59.2 5539

807 Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. **2015**, 22, 63 4

806 Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. **2015**, 212, 1125-37 242

805 Phase I trials in oncology: a new era has started. **2015**, 26, 7-9 17

804 Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. **2015**, 7, 275ra22 301

803 Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. **2015**, 21, 3113-20 87

802 T cell exclusion, immune privilege, and the tumor microenvironment. **2015**, 348, 74-80 1156

801 Recent advances in the field of anti-cancer immunotherapy. **2015**, 3, 280-8 54

800	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. <b>2015</b> , 3, 3	63
799	Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction. <b>2015</b> , 1-14	
798	Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax $\square$ platform in the treatment of glioblastoma multiforme. <b>2015</b> , 4, 63-9	27
797	High-resolution genomic analysis: the tumor-immune interface comes into focus. <b>2015</b> , 16, 65	3
796	Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. <b>2015</b> , 62, 316-24	18
795	Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. <b>2015</b> , 49, 907-37	118
794	Building better monoclonal antibody-based therapeutics. <b>2015</b> , 15, 361-70	411
793	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. <b>2015</b> , 4, e237	82
792	MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. <b>2015</b> , 4, e985924	38
791	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <b>2015</b> , 21, 3347-3355	184
790	Programmed death-1 checkpoint blockade in acute myeloid leukemia. <b>2015</b> , 15, 1191-203	50
789	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. <b>2015</b> , 15, 689-702	9
788	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <b>2015</b> , 21, 3771-82	117
787	A gender factor in shaping T-cell immunity to melanoma. <b>2015</b> , 5, 8	11
786	PD-1/PD-L1 inhibitors. <b>2015</b> , 23, 32-8	358
785	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <b>2015</b> , 7, 107-21	8
784	The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. <b>2015</b> , 26, 1980-1987	78
783	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. <b>2015</b> , 35, 15-22	27

782	EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF- $\kappa$ B. <b>2015</b> , 463, 95-101	104
781	Non-small-cell lung cancer. <b>2015</b> , 1, 15009	352
780	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. <b>2015</b> , 37, 1088-95	54
779	Immunology and Immunotherapy of Breast Cancer. <b>2015</b> , 457-470	
778	Development of Personalized Combination Cancer Immunotherapy Based on the Patients' Immune Status. <b>2015</b> , 255-266	2
777	Costimulation in Lymphomas and Cancers. <b>2015</b> , 185-254	4
776	T-Cell Costimulation and Its Applications in Diseases. <b>2015</b> , 255-292	3
775	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. <b>2015</b> , 94, 1545-52	56
774	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. <b>2015</b> , 123, 75-84	6
773	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. <b>2015</b> , 368, 246-51	34
772	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <b>2015</b> , 37, 764-82	360
771	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. <b>2015</b> , 88, 117-23	35
770	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. <b>2015</b> , 33, 245-60	33
769	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E $\mu$ -TCL1 CLL mouse model. <b>2015</b> , 126, 212-21	82
768	Immunostimulators and Immunomodulators in Cancer Treatment. <b>2015</b> , 411-431	
767	Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics. <b>2015</b> , 43, 915-34	27
766	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. <b>2015</b> , 11, 133-40	9
765	Immunotherapy for non-small-cell lung cancer: the past 10 years. <b>2015</b> , 11, 2681-2695	6

764	Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury. <b>2015</b> , 12, 361-7	13
763	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <b>2015</b> , 75, 2928-36	150
762	Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. <b>2015</b> , 21, 749-55	162
761	Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. <b>2015</b> , 21, 712-20	180
760	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <b>2015</b> , 3, 610-9	251
759	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. <b>2015</b> , 3, 506-17	198
758	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <b>2015</b> , 3, 1158-64	205
757	Image_1.TIF. <b>2020</b> ,	
756	Image_2.TIF. <b>2020</b> ,	
755	Image_3.TIF. <b>2020</b> ,	
754	Table_1.DOCX. <b>2020</b> ,	
753	Table_2.DOCX. <b>2020</b> ,	
752	Table_1.DOCX. <b>2019</b> ,	
751	Table_1.XLSX. <b>2020</b> ,	
750	Image_1.TIF. <b>2020</b> ,	
749	Image_2.TIF. <b>2020</b> ,	
748	Image_3.TIF. <b>2020</b> ,	
747	Image_4.TIF. <b>2020</b> ,	

746 Image\_5.TIF. 2020,

745 Image\_6.TIF. 2020,

744 DataSheet\_1.pdf. 2019,

743 Table\_1.DOCX. 2020,

742 Image\_1.TIF. 2020,

741 Table\_1.DOCX. 2020,

740 Table\_2.DOCX. 2020,

739 Table\_1.docx. 2019,

738 Data\_Sheet\_1.docx. 2018,

737 Image\_1.jpeg. 2019,

736 Image\_2.jpeg. 2019,

735 Image\_3.jpeg. 2019,

734 Image\_4.jpeg. 2019,

733 Image\_5.jpeg. 2019,

732 Table\_1.docx. 2019,

731 Table\_1.XLSX. 2019,

730 Data\_Sheet\_1.pdf. 2020,

729 Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. 2022,  
21, 250-268

2

728	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.. <b>2022</b> , 1	0
727	Interferon- $\gamma$ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.. <b>2022</b> , 12, 6657	0
726	A variety of 'exhausted' T cells in the tumor microenvironment.. <b>2022</b> ,	0
725	Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer.. <b>2022</b> , 50, 3000605221093222	0
724	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. <b>2021</b> , 83, 827-840	1
723	CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER.. <b>2019</b> , 58, 76-81	
722	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis.. <b>2022</b> ,	1
721	Cancer stem cells: a major culprit of intra-tumor heterogeneity.. <b>2021</b> , 11, 5782-5811	
720	OUP accepted manuscript.	0
719	High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model.. <b>2022</b> , 14,	0
718	Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer.. <b>2022</b> , 14,	0
717	Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.. <b>2022</b> , 11, 670-685	0
716	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.. <b>2022</b> , 13, 829634	0
715	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.. <b>2022</b> , 14, 45	2
714	Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma.. <b>2022</b> ,	2
713	Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer. <b>2022</b> , 10, 1047	
712	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma.. <b>2022</b> , 13, 863796	
711	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.. <b>2022</b> , 219,	2

710	Companion Diagnostics.. <b>2022,</b>	
709	Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).. <b>2022, 22, 462</b>	0
708	Prospect of radiotherapy technology development in the era of immunotherapy. <b>2022,</b>	1
707	A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma.. <b>2022, 12, 817916</b>	0
706	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. <b>2022, 13,</b>	0
705	Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. <b>2022, 12, 659</b>	
704	Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. <b>2022, 40, 45-74</b>	3
703	Distinct phenotypic states and spatial distribution of CD8 T cell clonotypes in human brain metastases.. <b>2022, 3, 100620</b>	2
702	Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.. <b>2022, 11, 2073010</b>	0
701	Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy.. <b>2022, 23,</b>	1
700	Prognostic Value and Therapeutic Perspectives of CXCR Members in the Glioma Microenvironment.. <b>2022, 13, 787141</b>	0
699	Advanced Materials for Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors. <b>2022, 110738</b>	
698	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.. <b>2022, 132,</b>	6
697	Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases. <b>2022, 120275</b>	0
696	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. <b>2022, 14,</b>	2
695	The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.. <b>2022,</b>	0
694	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma.. <b>2022, 34, 315-324</b>	0
693	The Tmod cellular logic gate as a solution for tumor-selective immunotherapy.. <b>2022, 109030</b>	



692	Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies. <b>2022</b> , 12,	1
691	Prognostic Risk Signature and Comprehensive Analyses of Endoplasmic Reticulum Stress-Related Genes in Lung Adenocarcinoma.. <b>2022</b> , 2022, 6567916	0
690	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature.. <b>2022</b> , 11,	0
689	Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.. <b>2022</b> , 13, 752065	2
688	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. <b>2022</b> , 108, 108803	0
687	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.. <b>2022</b> , 347, 175-182	0
686	Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy.. <b>2022</b> , 186, 114321	3
685	Exploring the association of intratumoral immune cell infiltrates with histopathologic grade in canine mast cell tumors.. <b>2022</b> , 147, 83-91	0
684	Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View.. <b>2022</b> , 42, 1-8	0
683	Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review).. <b>2022</b> , 60,	0
682	Immunotherapy for Colorectal Cancer.. <b>2022</b> ,	
681	Immune responses of patients without cancer recurrence after a cancer vaccine over a long term. <b>2022</b> , 16,	
680	FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma. <b>2022</b> , 2022, 1-11	0
679	Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer. <b>2022</b> , 2022, 1-27	0
678	Immuno-onco-metabolism and Therapeutic Resistance. <b>2022</b> , 45-89	3
677	Cyclophilin A represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein.. <b>2022</b> ,	
676	Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer. <b>2022</b> , 12,	
675	A novel four-gene signature predicts immunotherapy response of patients with different cancers.. <b>2022</b> , e24494	1

674	Cancer Immunoediting in the Era of Immuno-oncology.. <b>2022</b> ,	0
673	Systemic immune dysfunction in cancer patients driven by IL6 induction of LAG3 in peripheral CD8+ T cells.. <b>2022</b> ,	0
672	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.. <b>2022</b> , 42, 1-14	1
671	Biomarkers for Cancer Immunotherapy. <b>2022</b> , 229-247	
670	Comprehensive Analysis of the Butyrate-Metabolism-Related Gene Signature in Tumor Microenvironment-Infiltrating Immune Cells in Clear Cell Renal Cell Carcinoma. <b>2022</b> , 10,	0
669	Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.	0
668	Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm.	0
667	Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer. <b>2022</b> , 12,	0
666	Necroptosis is Related to Anti-PD-1 Treatment Response and Influences the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. <b>2022</b> , 13,	0
665	Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. <b>2022</b> ,	2
664	Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives. <b>2022</b> , 108, 108882	0
663	The role of neoantigens in tumor immunotherapy. <b>2022</b> , 151, 113118	2
662	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. <b>2022</b> , 1-17	0
661	Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. <b>2022</b> , 1-12	0
660	Traitement de 1re ligne des CBNPC mÉastatiques sans addiction oncogÉnique. <b>2022</b> , 14, 1S52-1S67	
659	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. 13,	1
658	Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States.	
657	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. 13,	1

- 656 Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. 13, 1
- 655 Estimating the replicability of highly cited clinical research (2004-2018).
- 654 FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. 2022, 0
- 653 Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. 1
- 652 Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia.
- 651 Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. 2022, 20, 1
- 650 Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes. 0
- 649 European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. 2022, 5
- 648 The Chemokines Initiating and Maintaining Immune Hot Phenotype Are Prognostic in ICB of HNSCC. 2022, 13,
- 647 Integrated pan-cancer analysis reveals distinct clinical, genomic and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia. 2022,
- 646 The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. 2022, 9,
- 645 Tuning Surface Plasmon Resonance Responses through Size and Crosslinking Control of Multivalent Protein Binding-Capable Nanoscale Hydrogels. 1
- 644 Immunotherapy and Antivascular Targeted Therapy in Patients Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. 2022, 2022, 1-13
- 643 Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. 2022, 12, 0
- 642 KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. 2022, 9, 0
- 641 CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy. 2022, 543-553
- 640 Krebs von den Lungen-6 (KL-6), soluble programmed cell death-1 (sPD-1) and its ligand-1 (sPDL-1) in systemic sclerosis patients: Relation to disease parameters. 2022, 44, 333-337
- 639 Diagnosis and management of cardiomyopathy and heart failure during cancer treatment. 2023, 138-145

- 638 Lung cancer. **2023**, 336-340
- 637 Understanding the tumor microenvironment in head and neck squamous cell carcinoma. **2022**, 11, 0
- 636 The Significance and Relationship Between Siglec15 and PD-L1 in Colon Adenocarcinoma.
- 635 Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy. **2022**, 8, 692-704 2
- 634 De novo design of site-specific protein interactions with learned surface fingerprints. 0
- 633 Safety of sequential immune checkpoint inhibitors after prior immune therapy.
- 632 Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. **2022**, 22,
- 631 Radiopharmaceuticals as Novel Immune System Tracers. **2022**, 100936
- 630 Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. **2022**, 27, 3798 5
- 629 Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. 0
- 628 The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. **2022**, 10, e004312 1
- 627 Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. **2022**, 10, e004771 0
- 626 Recent Advances and Clinical Pharmacology Aspects of Chimeric Antigen Receptor ( CAR ) T-Cellular Therapy Development. 1
- 625 Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples. jclinpath-2022-208215
- 624 Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment. **2022**, 12,
- 623 Symptom clusters and their predictors in lung cancer patients treated with programmed cell death protein 1 (PD-1) immunotherapy. **2022**, 100103 0
- 622 Injectable DNA Hydrogel-Based Local Drug Delivery and Immunotherapy. **2022**, 8, 400 3
- 621 Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. 13, 1

620	Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. <b>2022</b> , 14, 2867	2
619	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
618	Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. 12,	
617	Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition.	0
616	Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. <b>2022</b> , 11,	1
615	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. 12,	1
614	Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. <b>2022</b> , 119,	5
613	Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. 10,	0
612	Resveratrol in cancer treatment with a focus on breast cancer. <b>2022</b> , 15,	
611	Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. <b>2022</b> , 2022, 1-8	
610	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <b>2022</b> , 132,	0
609	Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma. <b>2022</b> , 14, 2936	0
608	Non-cytotoxic Nanoparticles Re-educating Macrophages Achieving both Innate and Adaptive Immune Responses for Tumor Therapy. <b>2022</b> ,	0
607	BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma. <b>2022</b> , 10, e004133	0
606	Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer. 13,	
605	Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. gutjnl-2021-325808	1
604	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.	15
603	Targeting Chromatin Effector Pygo2 to Enhance Immunotherapy in Prostate Cancer.	

- 602 Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. **2022**, 12, 958
- 601 Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF- $\beta$  degradation. **2022**, 13, 2
- 600 Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. **2022**, 176, 103746
- 599 Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. **2022**, 110, 108900 3
- 598 Lung Adenocarcinoma Patients with Malignant Pleural Effusions in Hot Adaptive Immunity Status Have a Longer Overall Survival.
- 597 Elevated Expression Levels of Neutrophil Related Chemokine Citrullinated Histone H3, Interleukin-8 and C- Reactive Protein in Patients with Immune Checkpoint Inhibitor Therapy: Predictive Biomarkers for Response to Treatment.
- 596 Inflammation Markers Have Important Value in Predicting Relapse in Patients with papillary thyroid carcinoma: A Long-Term Follow-Up Retrospective Study. **2022**, 29, 107327482211152 1
- 595 A combination of stromal PD-L1 and tumoral nuclear  $\beta$ -catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma. 0
- 594 The Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia. 1
- 593 Network-based machine learning approach to predict immunotherapy response in cancer patients. **2022**, 13, 1
- 592 Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts. 9,
- 591 Real-world utilization of PD -1/ PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer. 0
- 590 Charting roadmaps towards novel and safe synergistic immunotherapy combinations. **2022**, 3, 665-680 0
- 589 PD-L1 Up-Regulation in Prostate Cancer Cells by *Porphyromonas gingivalis*. 12, 1
- 588 PD-L1 in gestational trophoblastic disease: an antibody evaluation.
- 587 Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Controlled Trial-Based Network Meta-Analysis. **2022**, 2022, 1-20
- 586 Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. 0
- 585 Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2. **2022**, 102857 0

584	Dynamic Analysis of a Model on Tumor-Immune System with Regulation of PD-1/PD-L1 and Stimulation Delay of Tumor Antigen. <b>2022</b> , 21,	0
583	Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.	
582	A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. 12,	0
581	Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. 13,	2
580	Sequence-specific 1H, 13C and 15N backbone NMR assignments for the N-terminal IgV-like domain (D1) and full extracellular region (D1D2) of PD-L1.	1
579	Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid. <b>2022</b> , 11,	
578	ITCH facilitates proteasomal degradation of TXNIP in hypoxia- induced lung cancer cells.	1
577	Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer.	1
576	Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma. 13,	1
575	mRNA vaccine development for cholangiocarcinoma: a precise pipeline. <b>2022</b> , 9,	0
574	Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer.	2
573	CpG ODN (K3) Toll-like receptor 9 agonist induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. <b>2022</b> , 22,	0
572	Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells. <b>2022</b> , 23, 7922	0
571	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. 12,	0
570	Tumor and dendritic cell dual-targeting nanocarriers maximize the therapeutic potential of IDO1 inhibitor in vivo.	0
569	Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. <b>2022</b> ,	1
568	SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma. 13,	
567	CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. 9,	0

566	Clinically-meaningful improvements in therapy for unresectable NSCLC.	0
565	Targeting CD47 as a Novel Immunotherapy for Breast Cancer. 12,	1
564	The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion. 13,	1
563	Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. <a href="#">gutjnl-2021-326553</a>	0
562	Pulmonary adverse events following immune checkpoint inhibitors. Publish Ahead of Print,	0
561	Nivolumab plus ipilimumab in malignant pleural mesothelioma.	0
560	Retrospective Study of Clinical Outcomes and Toxicity Profile in Patients Treated with Immune Checkpoint Inhibitors.	
559	Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. <b>2022</b> , 13,	1
558	Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. <b>2022</b> , 13,	0
557	Gut Microbiota and Immunotherapy. 13,	3
556	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.	0
555	Facts and hopes for immunotherapy in renal cell carcinoma.	2
554	Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. 13,	0
553	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer. 10,	0
552	POLE/POLD1 mutation and tumor immunotherapy. <b>2022</b> , 41,	5
551	Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. <b>2022</b> , 13,	4
550	The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.	
549	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. 13,	



548	Dostarlimab: A breakthrough in the field of oncology. <b>2022</b> , 80, 104046	
547	Irradiation combined with PD-L1 $\uparrow$ and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. <b>2022</b> , 25, 104690	1
546	The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer. <b>2022</b> , 89, 120-127	0
545	Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. <b>2022</b> , 171, 3-8	
544	A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. 13,	0
543	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. 28,	0
542	Current State of Cell Therapies for Genitourinary Malignancies. <b>2022</b> , 28, 294-300	0
541	Host STING is essential for the efficacy of anti-PD -1 inhibitors in non-small cell lung cancer.	0
540	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. 13,	
539	Predicting cancer immunotherapy response from gut microbiomes using machine learning models. <b>2022</b> , 13, 876-889	1
538	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. 13,	0
537	Interferon- $\beta$ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients.	0
536	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. <b>2022</b> , 10, e004879	0
535	Regulatory T-cell development in the tumor microenvironment.	4
534	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. 3,	1
533	Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. <b>2022</b> , 11,	0
532	A Protein Kinase D Inhibitor Suppresses AKT on T cells and Antagonizes Cancer Immunotherapy by Anti-PD-1.	0
531	Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells.	0

- 530 The HIV Reservoir and Cure and Remission Strategies. **2021**, 199-217
- 529 Response assessment in neuro-oncology criteria. **2022**, 491-499
- 528 CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy. 0
- 527 Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
- 526 Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer. **2022**, 22,
- 525 Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. **2022**, 12,
- 524 A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. 13, 0
- 523 Clinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma. 12, 0
- 522 Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. **2022**, 13, 907-917
- 521 Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients. **2022**, 10, 1827 0
- 520 Overexpression of 14-3-3 $\beta$  primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. **2022**, 14, 5838-5854 1
- 519 Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. 13, 1
- 518 The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. 13, 4
- 517 Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. 13,
- 516 Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. 13, 0
- 515 Grade 3/4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. **2022**, 14, 3878 1
- 514 Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy. **2022**, 15, 100276 0
- 513 Recent Advances and Challenges in Cancer Immunotherapy. **2022**, 14, 3972 3

512	Bias and inconsistency in the estimation of tumour mutation burden. <b>2022</b> , 22,	0
511	Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. <b>2022</b> ,	1
510	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12,	2
509	Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model. 1-13	
508	TGF $\beta$ signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy. 1-16	0
507	Modeling Resistance to Immune Checkpoint Blockade. <b>2022</b> , 107-149	
506	Identification of A Six Immune-Related Genes Prognostic Signature and Exploration of Individual Therapies in Young Women with Cervical Cancer.	
505	Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma.	
504	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. <b>2022</b> , 15,	2
503	Lactate score predicts survival, immune cell infiltration and response to immunotherapy in breast cancer. 13,	
502	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. <b>2022</b> , 22,	2
501	Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.	
500	Co-Delivery of Doxorubicin and Anti-PD-L1 Peptide in Lipid/PLGA Nanocomplexes for the Chemo-Immunotherapy of Cancer.	1
499	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. <b>2022</b> , 10, 1872	2
498	Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer.	
497	Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection. <b>2022</b> , 23,	0
496	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. <b>2022</b> , 41, 202-209	0
495	Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. 2103677	1

- 494 A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma. 0
- 493 Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. **2022**, 10, e004761 3
- 492 Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
- 491 Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab. **2022**, 0
- 490 Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. 13,
- 489 Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. **2022**, 40, 111256 1
- 488 Predictive value of focal adhesion-related genes for prognosis and response to immunotherapy in glioma patients.
- 487 Ocular Inflammation Induced by Immune Checkpoint Inhibitors. **2022**, 11, 4993 1
- 486 Protein-Delivering Nanocomplexes with Fenton Reaction-Triggered Cargo Release to Boost Cancer Immunotherapy. 0
- 485 Comprehensive Analysis of the Prognostic Value and Immune Infiltration of Butyrophilin Subfamily 2/3 (BTN2/3) Members in Pan-Glioma. 12, 0
- 484 Next Steps for Immunotherapy in Glioblastoma. **2022**, 14, 4023 1
- 483 A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. 13, 1
- 482 Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma. 13, 0
- 481 The role of PD-1/PD-L1 inhibitors in the treatment for non-small cell lung cancer (NSCLC). 8, 41-49
- 480 The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.
- 479 Immunotherapeutic targets in non-small cell lung cancer. 1
- 478 Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to AntiPD-L1 Immune Checkpoint Therapy. 0
- 477 Cold Atmospheric Plasma Targeting Hematological Malignancies: Potentials and Problems of Clinical Translation. **2022**, 11, 1592 1

476	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. 12,	
475	Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. <b>2022</b> , 40, 1021-1031	0
474	BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma. <b>2022</b> ,	0
473	TGF- $\beta$ regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection. <b>2022</b> , 219,	1
472	Neobavaisoflavone inhibits antitumor immunosuppression via myeloid-derived suppressor cells. <b>2022</b> , 111, 109103	0
471	Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. 13,	0
470	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <b>2022</b> , 41,	2
469	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. <b>2022</b> , 73, 117001	2
468	Successes and failures of immunotherapy for gastric cancer. <b>2022</b> , 27, 103343	0
467	Molecular imaging of immune checkpoints in oncology: Current and future applications. <b>2022</b> , 548, 215896	0
466	Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends. <b>2022</b> , 239, 108276	0
465	Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer. <b>2022</b> , 20, 3911-3923	1
464	Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer. <b>2022</b> , 20, 5440-5452	0
463	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. <b>2022</b> , 91-111	0
462	Epigenetic Mediated Regulation of Cancer-Testis/Germline Antigen and Its Implication in Cancer Immunotherapy: A Treasure Map for Future Anticipatory Medicine. <b>2022</b> , 149-166	0
461	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. <b>2022</b> , 13, 10897-10903	2
460	Available immunotherapies and future opportunities to prevent HPV-associated cancers. <b>2022</b> , 165-204	0
459	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. <b>2022</b> , 29, 107327482211112	0

458	Bioprospection and Clinical Investigations of Immunomodulatory Molecules. <b>2022</b> , 53-81	0
457	Targeting tumor microenvironment for breast cancer treatment. <b>2022</b> , 249-277	1
456	CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis. 13,	0
455	Leveraging big data of immune checkpoint blockade response identifies novel potential targets. <b>2022</b> ,	1
454	T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. <b>2022</b> , 14, 4246	0
453	Systematic identification of cancer-associated-fibroblast-derived genes in patients with colorectal cancer based on single-cell sequencing and transcriptomics. 13,	0
452	Neoantigen vaccine and neoantigen-specific cell adoptive transfer therapy in solid tumors: Challenges and future directions. <b>2022</b> , 1, 168-182	0
451	High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals. <b>2022</b> , 13,	1
450	Cardiovascular complications of immune checkpoint inhibitors for cancer.	2
449	Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China. <b>2022</b> , 2022, 1-8	0
448	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.	2
447	PD-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and Foxp3 stability. <b>2022</b> , 13,	1
446	The contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation and microbiota. <b>2022</b> , 111829	0
445	What does radiomics do in PD-L1 blockade therapy of NSCLC patients?. <b>2022</b> , 13, 2669-2680	0
444	GPNMB: a potent inducer of immunosuppression in cancer. <b>2022</b> , 41, 4573-4590	0
443	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after IFN- $\gamma$ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer	1
442	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. 13,	0
441	MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. <b>2022</b> ,	1

440	Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors. <b>2022</b> , 14, 044105	0
439	Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. OF1-OF15	0
438	Tumor-Homing and Immune-Reprogramming Cellular Nanovesicles for Photoacoustic Imaging-Guided Phototriggered Precise Chemoimmunotherapy.	0
437	Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma. Volume 14, 2723-2731	0
436	Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade. <b>2022</b> , 28, 4121-4130	4
435	m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent. 13,	0
434	An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. <b>2022</b> , 219,	0
433	miR-acious new avenues for cancer immunotherapy. 13,	0
432	Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. <b>2022</b> , 11, 3028	2
431	Novel targets for immunotherapy associated with exhausted CD8 + T cells in cancer.	0
430	The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer. <b>2022</b> , 10, 1451	0
429	Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer. <b>2022</b> ,	0
428	Efficacy of Different Treatments for Patients with Advanced Hepatocellular Carcinoma: A System Review and Network Meta-Analysis. <b>2022</b> , 7, 58	0
427	Dynamics of cancerous tumors under the effect of delayed information: mathematical and electronic study.	0
426	Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. 12,	0
425	Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model. <b>2022</b> , 17, e0273076	0
424	ICBatlas: A comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles.	0
423	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). <b>2022</b> , 10, e005413	0

- 422 Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. **2022**, 2022, 1-9 ○
- 421 The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model. ○
- 420 In vitro models as tools for screening treatment options of head and neck cancer. 9, ○
- 419 Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy. **2022**, 10, 1552 ○
- 418 Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma. 9, ○
- 417 Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. **2022**, 8, ○
- 416 Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. **2022**, 14, 4473 2
- 415 Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy. 9, ○
- 414 Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. 13, ○
- 413 Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases. ○
- 412 Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. ○
- 411 Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. **2022**, 19, 1153-1167 ○
- 410 Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. **2022**, 9, ○
- 409 A Bayesian phase I/ II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy. ○
- 408 Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. **2022**, 2022, ○
- 407 Telomere-Associated Changes in Nuclear Architecture of Cancer-Associated Macrophage-like Cells in Liquid Biopsies from Melanoma Patients. **2022**, 10, 2391 ○
- 406 Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. 1-10 ○
- 405 Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer. 12, 1



404	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <b>2022</b> , 23, 9985	2
403	Enzymatic Nanosphere-to-Nanofiber Transition and Autophagy Inducer Release Promote Tumor Chemotherapy. 2201916	0
402	T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. 13,	1
401	Seq2Neo: a comprehensive pipeline for cancer neoantigen immunogenicity prediction.	0
400	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. 13,	0
399	The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis. <b>2022</b> , 14, 4287	1
398	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. <b>2022</b> , 10, 2211	1
397	Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy. <b>2022</b> , 11, 2802	0
396	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
395	Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation. 12,	0
394	CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab. Publish Ahead of Print,	0
393	Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. 10,	1
392	A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis. <b>2022</b> ,	0
391	Anti-tumour potential of PD-L1 / PD -1 post-translational modifications.	0
390	Fibrotic immune microenvironment remodelling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. <b>2022</b> ,	1
389	Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance.	0
388	The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. <b>2022</b> ,	0
387	The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.	0

- 386 Technology meets TILs: Deciphering T cell function in the -omics era. **2022**, 0
- 385 Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. 13, 0
- 384 Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer. 13, 1
- 383 A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. 0
- 382 Lipid metabolic features of T cells in the Tumor Microenvironment. **2022**, 21, 0
- 381 CD8 + T cell exhaustion in anti-tumor immunity: the new insights for cancer immunotherapy. 1
- 380 Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization. **2022**, 10, e005103 1
- 379 THE DNA DAMAGE INDUCED IMMUNE RESPONSE: IMPLICATIONS FOR CANCER THERAPY. **2022**, 103409 0
- 378 Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. 13, 0
- 377 Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. OF1-OF11 0
- 376 Lung adenocarcinoma patients with malignant pleural effusions in hot adaptive immunity status have a longer overall survival. 12, 0
- 375 A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). **2022**, 11, 2
- 374 Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer. 0
- 373 *Brucea javanica* oil emulsion significantly improved the effect of anti-programmed cell death protein-1 immunotherapy. **2022**, 107, 154446 0
- 372 Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. **2022**, 14, 175883592211338 0
- 371 AKT Isoforms in the Immune Response in Cancer. **2022**, 349-366 0
- 370 Polyethyleneimine-based immunoadjuvants for designing cancer vaccines. **2022**, 10, 8166-8180 0
- 369 PD-1 Relevant Genes Predict the Prognosis of Breast Cancer and Their Prediction Effect in Tumor Response to Immunotherapy. **2022**, 1-14 0

- 368 Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy. **2022**, 14, 4796 1
- 367 Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Volume 9, 1109-1125 0
- 366 Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma. Publish Ahead of Print, 0
- 365 A Hybrid Discrete-Continuum Modelling Approach to Explore the Impact of T-Cell Infiltration on Anti-tumour Immune Response. **2022**, 84, 0
- 364 Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. **2022**, 23, 12067 0
- 363 Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer. 13, 0
- 362 Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis. 12, 0
- 361 Research on the influence of APOBEC family on the occurrence, diagnosis, and treatment of various tumors. 0
- 360 Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. **2022**, 10, e004781 0
- 359 Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?. 13, 1
- 358 Cancer Genomics and Evolution. 1-30 0
- 357 Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. **2022**, 10, 2628 0
- 356 Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy. **2022**, 14, 5008 1
- 355 Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 /anti-PSMA bispecific design. 0
- 354 The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. **2022**, 185, 4049-4066.e25 3
- 353 Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. **2022**, 13, 2
- 352 Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction. **2022**, 23, 11624 0
- 351 Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients. 13, 0

350	Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. <b>2022</b> , 10, e005573	1
349	Oncolytic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. <b>2022</b> , 23, 12647	0
348	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. 13,	0
347	Oncologic Emergencies. 1-21	0
346	Epigenetic Contributions to Human Cancer. 1-13	0
345	Neoplasms of the Prostate. 1-46	0
344	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <b>2022</b> , 23, 13241	0
343	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. 13,	0
342	A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone. <b>2022</b> , 4, 211-213	0
341	Neoplasms of the Head and Neck. 1-28	0
340	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.	0
339	Genomic instability, origin and evolution of cancer, and personalized immunotherapy. <b>2022</b> ,	0
338	Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy.	0
337	Melanoma classification and management in the era of molecular medicine. <b>2022</b> ,	3
336	Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. 13,	0
335	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. <b>2022</b> , 14, 5332	1
334	Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. <b>2022</b> , 14, 2225	3
333	A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood. 1-17	1

- 332 Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. **2022**, 23, 12991 ○
- 331 Cancer of the Lung. 1-29 ○
- 330 The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. **2022**, 13, ○
- 329 Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that INHIBITS the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. **2022**, 106196 ○
- 328 Engineered anti-PDL1 with IFN $\gamma$  targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. *gutjnl-2022-327059* 1
- 327 Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. 0272989X2211322 ○
- 326 Hsp90 $\alpha$  inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. 13, ○
- 325 The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis. 12, ○
- 324 Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy. 1
- 323 Selection of a PD -1 blocking antibody from a novel fully human phage display library. ○
- 322 Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. **2022**, 103863 ○
- 321 IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma. **2022**, 18, 1319-1327 ○
- 320 A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. 12, ○
- 319 Nociceptor neurons affect cancer immunosurveillance. ○
- 318 Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. ○
- 317 The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. **2022**, 11, 1521 ○
- 316 A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma. **2022**, 20, ○
- 315 Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. **2022**, ○

- 314 Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice. **2022**, 8, ○
- 313 Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. **2022**, 58, 1572 ○
- 312 Automated analysis of PD1 and PDL1 in lymph nodes and the microenvironment of transmissible tumors in Tasmanian devils. ○
- 311 Advances in immunotherapy for MMR proficient colorectal cancer. **2022**, 111, 102480 1
- 310 The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138 ○
- 309 Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy. **2022**, 291, 121880 ○
- 308 A single dose of heated chemo-immunotherapy for long-term tumor inhibition. **2022**, 47, 101650 ○
- 307 CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial. **2022**, 7, 100594 ○
- 306 Targeted therapy and molecular genetics. **2023**, 464-488.e11 ○
- 305 Comprehensive landscape and future perspectives of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC): Based on a bibliometric analysis. **2023**, 8, 33-52 ○
- 304 Cancer-cell-intrinsic mechanisms regulate MDSCs through cytokine networks. **2022**, ○
- 303 Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. **2022**, ○
- 302 Weaponizing natural killer cells for solid cancer immunotherapy. **2022**, ○
- 301 Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment. Volume 17, 5391-5411 ○
- 300 Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. 12, ○
- 299 Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. 9, ○
- 298 Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. 13, ○
- 297 The efficacy of chemotherapy is limited by intratumoural senescent cells that persist through the upregulation of PD-L2. ○

296	Homotypic Targeted Photosensitive Nanointerferer for Tumor Cell Cycle Arrest to Boost Tumor Photoimmunotherapy.	0
295	Host Molecule Incorporation into HIV Virions, Potential Influences in HIV Pathogenesis. <b>2022</b> , 14, 2523	1
294	Ferroptosis: a double-edged sword mediating immune tolerance of cancer. <b>2022</b> , 13,	1
293	A novel immune signature predicts immunotherapy responsiveness and reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma. 13,	0
292	The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes. <b>2022</b> , 22,	0
291	AntiPD-L1 antibody conjugated Au-SPIOs nanoplatfom for enhancing radiosensitivity and triggering anti-tumor immune response. <b>2022</b> , 12,	1
290	Low-dose nivolumab in advanced hepatocellular carcinoma. <b>2022</b> , 22,	1
289	Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis. 12,	0
288	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. <b>2022</b> , 10, 2809	0
287	Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer. 13,	0
286	Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score Matching Study. <b>2022</b> , 46, 88-95	0
285	Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study. <b>2022</b> , 86, 104364	1
284	Dry and wet experiments reveal the significant role of FUT11 in clear cell renal cell carcinoma. <b>2022</b> , 113, 109447	0
283	REFINE (REduced Frequency ImmUNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. <b>2023</b> , 124, 107030	0
282	Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation. <b>2023</b> , 228, 152311	0
281	An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). <b>2022</b> , 14, 175883592211383	0
280	Analysis of top-cited articles on melanoma. <b>2022</b> , 31,	0
279	Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy. <b>2023</b> , 246, 109204	0

- 278 Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer. 34, ○
- 277 Novel biomimetic mesoporous silica nanoparticle system possessing targetability and immune synergy facilitates effective solid tumor immuno-chemotherapy. **2023**, 144, 213229 ○
- 276 PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration. **2023**, 555, 216034 ○
- 275 Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: A French nationwide study from the Epithor cohort database. **2023**, 26, 100566 ○
- 274 Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers. **2023**, 8, 101038 ○
- 273 Stability and Hopf bifurcation of a tumor-immune system interaction model with an immune checkpoint inhibitor. **2023**, 118, 106996 ○
- 272 Shifting Treatment Paradigms in Non-Hodgkin Lymphomas. 35-43 ○
- 271 Immunotherapy. **2022**, 309-328 ○
- 270 Immunotherapy and Endocrine Oncology. **2022**, 1-36 ○
- 269 Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. 100-107 ○
- 268 The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy. 42-48 ○
- 267 The landscape of TIGIT target and clinical application in diseases. **2022**, 1, ○
- 266 Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. **2022**, 10, 2049 ○
- 265 Nanoparticle-Delivered Transforming Growth Factor- $\beta$  siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment. **2022**, 15, 1487 ○
- 264 Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser. **2022**, 14, 5815 ○
- 263 The association of HHLA2 and PD-L1 expression with prognosis and immune microenvironment in hepatocellular carcinoma. ○
- 262 Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis. **2022**, 10, e005132 ○
- 261 Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review. **2022**, ○



260	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.	2
259	Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. <b>2022</b> , 29, 9046-9065	0
258	Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. 13,	1
257	Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. <b>2022</b> , 14, 5727	0
256	Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. <b>2022</b> , 23, 15006	0
255	Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. <b>2022</b> , 11, 3769	0
254	Magnetic Resonance-Guided Adaptive Radiotherapy for Prostate Cancer: The First Results from the MOMENTUM study, an International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiotherapy. <b>2022</b> ,	0
253	Pulmonary effects of cancer treatments. <b>2022</b> , 253-264	0
252	Immune-related colitis and pancreatitis treated with infliximab.	0
251	ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. <b>2022</b> , 13,	1
250	The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer. <b>2022</b> , 14, 5685	0
249	Mechanisms of colorectal liver metastasis development. <b>2022</b> , 79,	0
248	Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. <b>2022</b> ,	0
247	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer.	0
246	Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. <b>2022</b> , 6,	0
245	Decreased B7-H3 promotes unexplained recurrent miscarriage via RhoA/ROCK2 signaling pathway and regulates the secretion of decidual NK cells.	1
244	CD244 regulates both innate and adaptive immune axes in melanoma by inhibiting autophagy-mediated M1 macrophage maturation.	0
243	Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene. 1-94	0

- 242 Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma. **2022**, 0
- 241 Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study. **2023**, 15, 0
- 240 Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. 13, 0
- 239 Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. **2022**, 23, e552-e561 1
- 238 Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling. **2023**, 86, 0
- 237 A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. 13, 1
- 236 TGF- $\beta$ A novel predictor and target for anti-PD-1/PD-L1 therapy. 13, 1
- 235 Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance. 0
- 234 Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series. **2022**, 12, 12994 0
- 233 A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. **2023**, 24, 156 0
- 232 Integrated molecular analyses of an interferon- $\beta$ -based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. **2022**, 8, e12102 0
- 231 Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients. 0
- 230 Fibroblast Programmed Cell Death Ligand 1 Promotes Osteoclastogenesis in Odontogenic Keratocysts. **2022**, 0
- 229 Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. 0
- 228 Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. 0
- 227 Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell-mediated cytotoxicity and PD-1 checkpoint. **2022**, 22, 0
- 226 Neoadjuvant immunotherapy for resectable esophageal cancer: A review. 13, 0
- 225 Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. **2022**, 3, 101886 0

224	Dual-Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis. 2209379	0
223	Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.	0
222	Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer.	0
221	Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.	0
220	Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. 2022, 11, 12279	0
219	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. 2022, 7, 100646	0
218	Anti-TGF- $\beta$ /PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. 2022, 10, e005543	0
217	SPATA2 and CYLD inhibit T cell infiltration into colorectal cancer via regulation of IFN- $\gamma$ /STAT1 axis. 12,	0
216	Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8+ T cells in osteosarcoma. 153537022211426	0
215	Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement. 2022, 11, 4006	0
214	Rationale for LDH-Targeted Cancer Immunotherapy. 2022,	0
213	Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients.	1
212	Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. 2022, 40, 1600-1618.e10	1
211	TYK2 correlates with immune infiltration: A prognostic marker for head and neck squamous cell carcinoma. 13,	0
210	Viral delivery of a peptide-based immunomodulator enhances T cell priming during vaccination. 13,	0
209	Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report. 13,	0
208	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. 2023, 59, 23	0
207	Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy. 2022, 13,	0

- 206 Current Targeted Therapy for Metastatic Colorectal Cancer. **2023**, 24, 1702 1
- 205 Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry. **2023**, 0
- 204 Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. 0
- 203 The effect of Wnt/ $\beta$ -catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. **2022**, 30, 99-116 0
- 202 Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma. 12, 0
- 201 Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus. 0
- 200 PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer. 0
- 199 Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. **2023**, 133, 0
- 198 Editorial: Modulation of the immune system by bacteria: From evasion to therapy. 13, 0
- 197 Association of KMT2C /D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. 0
- 196 Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. **2023**, 24, 1280 1
- 195 The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. **2023**, 16, 0
- 194 Poria cocos polysaccharide-functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice. 10, 0
- 193 Sintilimab combined with chemotherapy successfully treated a patient with advanced submandibular gland tumor. 0
- 192 Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells. 13, 0
- 191 Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature. Publish Ahead of Print, 0
- 190 Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. 12, 0
- 189 Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma. 0

- 188 At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. 1
- 187 Mapping the interplay between NK cells and HIV: therapeutic implications. 0
- 186 Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. **2023**, 24, 818 0
- 185 Identification and characterization of nucleotide metabolism and neuroendocrine regulation-associated modification patterns in stomach adenocarcinoma with auxiliary prognostic assessment and immunotherapy response prediction. 13, 0
- 184 Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. 0
- 183 From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy. 10, 0
- 182 Characterization and outcome of RAC1 mutated melanoma. **2023**, 0
- 181 Transcriptional factors targeting in cancer stem cells for tumor modulation. **2023**, 88, 123-137 0
- 180 Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. **2023**, 12, 258 0
- 179 Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?. 0
- 178 Strahlentherapie und Immuntherapie. **2023**, 1-20 0
- 177 An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma. 12, 0
- 176 Recent advances in drug delivery systems for targeting brain tumors. **2023**, 30, 1-18 0
- 175 KANSER TANISI VE TEDAVİSİNDE KULLANILAN MONOKLONAL ANTİKORLAR. **2023**, 47, 2-2 0
- 174 Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. **2023**, 21, 0
- 173 Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. **2023**, 158, 114180 0
- 172 The exhaustion of lymphocytes is the main factor that decreases the sensitivity of QFT-GIT detection in silicosis. **2022**, 23, 0
- 171 Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. 1-5 0

- 170 Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. **2023**, 15, 246 ○
- 169 The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions. ○
- 168 Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. **2023**, 18, e0281143 1
- 167 Impact of Precision Medicine in Oncology. **2023**, 29, 15-19 ○
- 166 A Look at Emerging Therapeutic Targets for Gallbladder Cancer: A Multi-Omics Approach. **2023**, 161-175 ○
- 165 Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer. **2023**, ○
- 164 Innate Immune Program in Formation of Tumor-Initiating Cells from Cells-of-Origin of Breast, Prostate, and Ovarian Cancers. **2023**, 15, 757 ○
- 163 Hypoxia signaling in cancer: Implications for therapeutic interventions. **2023**, 4, 1
- 162 Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment. ○
- 161 Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. **2023**, 22, 153303382211505 ○
- 160 Nivolumab plus cabozantinib for advanced renal cell carcinoma. ○
- 159 Tumor immunology. **2023**, 245-452 ○
- 158 Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis. 10, ○
- 157 Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME). **2023**, ○
- 156 Clinical Plasma Cells-related Genes to Aid Therapy in Colon Cancer. ○
- 155 Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. **2023**, 86, ○
- 154 Immunotherapy in colorectal cancer: a beacon of hope. ○
- 153 Pyroptosis in urinary malignancies: a literature review. **2023**, 14, ○

- 152 Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data. 14,
- 151 A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. 12,
- 150 Biomaterials tools to modulate the tumour microenvironment in immunotherapy.
- 149 An in silico model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy. **2023**, 20,
- 148 High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. **2023**,
- 147 Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. **2023**, 121459
- 146 Imaging the immune cell in immunotherapy. **2023**, 197-238
- 145 Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. **2023**, 24, 2676
- 144 Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. 12,
- 143 Minimally invasive versus open McKeown esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant PD-1 inhibitor plus chemotherapy. 13,
- 142 Immunotherapies in rare cancers. **2023**, 22,
- 141 Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens.
- 140 Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. 13,
- 139 p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells.
- 138 Immunotherapy: Targeting Cancer Cells. **2023**, 179-217
- 137 A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. **2023**, 21, 2536-2546
- 136 Novel exosome-related risk signature as prognostic biomarkers in glioblastoma. 14,
- 135 Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.

- 134 PD-L1 Targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy. ○
- 133 Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer. **2023**, 15, 397-400 ○
- 132 Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?. ○
- 131 Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. ○
- 130 Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. **2023**, 117, 109881 ○
- 129 Oral lymphatic delivery of alpha-galactosylceramide and ovalbumin evokes anti-cancer immunization. **2023**, 356, 507-524 ○
- 128 The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. **2023**, 161, 114436 ○
- 127 Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer. **2023**, 38, e00794 ○
- 126 Machine learning revealed ferroptosis features and ferroptosis-related gene-based immune microenvironment in lung adenocarcinoma. **2023**, 378, 110471 ○
- 125 Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics. **2023**, 84, 104815 ○
- 124 A Novel Tri-Functional Liposome Re-Educes Cold Tumor and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade. 2202757 ○
- 123 Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. **2023**, 183, 103922 ○
- 122 SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. **2023**, 26, 106027 ○
- 121 A novel basement membrane-related gene signature for prognosis of lung adenocarcinomas. **2023**, 154, 106597 ○
- 120 Immune Checkpoint Inhibitors in Urological Cancers. **2023**, 1-25 ○
- 119 Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade. **2023**, 163, 156133 ○
- 118 Multi-antigen spherical nucleic acid cancer vaccines. ○
- 117 The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. **2023**, 24, 2805 1



116	Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Volume 14, 11-25	0
115	Identify AGAP2 as prognostic biomarker in clear cell renal cell carcinoma based on bioinformatics and IHC staining. <b>2023</b> , 9, e13543	0
114	Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. <b>2023</b> , 14,	0
113	Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. 13,	0
112	Overview of Chemotherapy for Gastric Cancer. <b>2023</b> , 12, 1336	1
111	Essential updates 2020/2021: Recent topics in surgery and perioperative therapy for esophageal cancer.	0
110	Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. <b>2023</b> , 11, e005640	0
109	The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.	0
108	GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis. <b>2023</b> , 9, e13617	0
107	Immunotherapy in Melanoma: Recent Advances and Future Directions. <b>2023</b> , 15, 1106	0
106	Optimizing the manufacturing and antitumour response of CAR T therapy. <b>2023</b> , 1, 271-285	0
105	Pan-Cancer Analysis of TASL: A Novel Immune Infiltration-Related Biomarker for Tumor Prognosis and Immunotherapy Response Prediction.	0
104	Waking immune-resistant tumors with neddylation. <b>2023</b> , 133,	0
103	Fast-evolving landscape of programmed death ligand (PD-L1) in cervical cancer. <b>2022</b> , 5, 767	0
102	Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab.	0
101	Cancer immunotherapies: A hope for the incurable?. 3,	0
100	Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing. <b>2023</b> , 38, 100884	0
99	p53 mutation and deletion contribute to tumor immune evasion. 14,	0

- 98 Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. **2023**, 15, 1314 ○
- 97 The Changing Landscape of Immunotherapy for Advanced Renal Cancer. **2023**, 50, 335-349 ○
- 96 Current Trends in Mucosal Melanomas: An Overview. **2023**, 15, 1356 ○
- 95 Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Publish Ahead of Print, ○
- 94 PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy. **2023**, 31, 197-203 ○
- 93 Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. ○
- 92 PD-L1, a Master Regulator of Immunity 2.0. **2023**, 24, 4385 ○
- 91 Interferon Gamma-Inducible NAMPT in Melanoma Cells Serves as a Mechanism of Resistance to Enhance Tumor Growth. **2023**, 15, 1411 ○
- 90 Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. **2023**, 46, 145-151 ○
- 89 Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. ○
- 88 YAP-controlled MHC-I and CXCL10 expression potentiates antitumor immunity independently of IFN $\gamma$  signaling. ○
- 87 Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies. 15, 222-233 ○
- 86 Pyodermitis during Nivolumab Treatment for Non-Small Cell Lung Cancer: A Case Report and Review of the Literature. **2023**, 24, 4580 ○
- 85 Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. **2023**, 11, e006234 ○
- 84 Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. **2023**, 15, 353-365 ○
- 83 Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. ○
- 82 Nanoparticle Targeting with Antibodies in the Central Nervous System. **2023**, 4, ○
- 81 Tumor-specific memory CD8<sup>+</sup> T cells are strictly resident in draining lymph nodes during tumorigenesis. **2023**, 20, 423-426 ○

- 80 Supplementation with ~~k~~etoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1. **2023**, 14, ○
- 79 RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. ○
- 78 N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer. 14, ○
- 77 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 76 Opportunities and challenges related to ferroptosis in glioma and neuroblastoma. 13, ○
- 75 The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography. Publish Ahead of Print, ○
- 74 Progression in immunotherapy for advanced prostate cancer. 13, 1
- 73 Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. **2023**, 156, 31-38 ○
- 72 Post-Translational Modification Impact on MHC Peptide Binding and TCR Engagement. ○
- 71 Current landscape and tailored management of immune-related adverse events. 14, ○
- 70 Immune Gene Therapy of Cancer. **2023**, 1-45 ○
- 69 Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. **2023**, 19, 259-270 ○
- 68 Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. **2023**, 15, 1679 ○
- 67 Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. **2023**, 8, ○
- 66 A data-driven Boolean model explains memory subsets and evolution in CD8+ T cell exhaustion. ○
- 65 Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. **2023**, 9, ○
- 64 The Potential Revolution of Cancer Treatment with CRISPR Technology. **2023**, 15, 1813 ○
- 63 Bioactive Compounds from the Mushroom-Forming Fungus *Chlorophyllum molybdites*. **2023**, 12, 596 ○

- 62 Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy. **2023**, 2023, 1-13 ○
- 61 Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. **2023**, 1-19 ○
- 60 Immunotherapies for advanced hepatocellular carcinoma. 14, ○
- 59 Tumors evade immune cytotoxicity by altering the surface topology of NK cells. ○
- 58 Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival. 13, ○
- 57 T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma. **2023**, 2, ○
- 56 Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. **2023**, 7, 281-297 ○
- 55 Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma. **2023**, 17, ○
- 54 Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. ○
- 53 The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress. **2023**, 124, 477-494 ○
- 52 Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. **2023**, 11, 1020 ○
- 51 Low-Dose Immunotherapy: Is It Just an Illusion?. **2023**, 11, 1032 ○
- 50 Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. ○
- 49 Steroid Receptor Coactivator-3 is a Key Modulator of Regulatory T Cell-Mediated Tumor Evasion. ○
- 48 Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. **2023**, 13, ○
- 47 Metrology and visualization analysis of literatures related to tumor immunotherapy based on CiteSpace. ○
- 46 An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma. **2023**, 13, ○
- 45 Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy. 10, ○

- 44 A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. 14,
- 43 T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. **2023**, 186, 1432-1447.
- 42 Construction of a novel prognostic model for evaluation of immune infiltration and immunotherapy in lung adenocarcinoma.
- 41 Crosstalk between triple negative breast cancer and microenvironment. **2023**, 14, 284-293
- 40 Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021. **2023**, 43, 289-298
- 39 AIM2 is a novel biomarker for predicting prognosis and immunotherapy response of clear cell renal cell carcinoma.
- 38 Re-evaluating the melanoma TIL compartment and its unexpected spectrum of exhausted and functional T cells.
- 37 Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells. **2023**, 2023, 1-13
- 36 Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes. 239936932311618
- 35 Clinical Characteristics and Human Leukocyte Antigens in patients with Immune Checkpoint Inhibitor-induced Type 1 Diabetes and Pituitary Dysfunction: A single center prospective study.
- 34 Newly developed 3D in vitro models to study tumor-immune interaction. **2023**, 42,
- 33 MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
- 32 The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens. **2023**, 67, 101758
- 31 Modulation of pancreatic tumor immunity by NKG2D T cells through MICB shedding.
- 30 Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. **2023**, 14,
- 29 Chronic diffuse lung diseases. **2024**, 231-302
- 28 Dietary tryptophan metabolite released by intratumoral *Lactobacillus reuteri* facilitates immune checkpoint inhibitor treatment. **2023**,
- 27 Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy. 14,

- 26 Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. **2023**, 42, 112364 ○
- 25 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073 ○
- 24 Active recruitment of antiPD-1 conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy. **2023**, 9, ○
- 23 Checkpointinhibitoren beim kolorektalen Karzinom Eine neue Era? ○
- 22 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 21 The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer. **2023**, 9, e15371 ○
- 20 Research Progress of Immunotherapy for Gastric Cancer. **2023**, 22, 153303382211505 ○
- 19 Immune checkpoint therapyCurrent perspectives and future directions. **2023**, 186, 1652-1669 ○
- 18 Camrelizumab for cancers in patients living with HIV: one-single center experience. **2023**, 20, ○
- 17 Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. 13, ○
- 16 Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report. 13, ○
- 15 Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma. **2023**, 6, e236356 ○
- 14 Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. **2023**, 30, 4246-4256 ○
- 13 A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. 14, ○
- 12 A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021. 14, ○
- 11 Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies; a rapidly evolving strategy. **2023**, 154473 ○
- 10 Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. **2023**, 154470 ○
- 9 Immunotherapy. **2023**, 489-540 ○

- 8 Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. **2023**, 23,
- 7 Extremely Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging. **2023**, 41, 181-205
- 6 De novo design of protein interactions with learned surface fingerprints. **2023**, 617, 176-184
- 5 Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. 14,
- 4 Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.
- 3 Inside PD-1/PD-L1,2 with their inhibitors. **2023**, 256, 115465
- 2 Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study.
- 1 The progress on the relationship between gut microbiota and immune checkpoint blockade in tumors. 1-20